

RESEARCH ARTICLE

Olig2 and Hes regulatory dynamics during motor neuron differentiation revealed by single cell transcriptomics

Andreas Sagner¹✉, Zachary B. Gaber²✉, Julien Delile¹✉, Jennifer H. Kong², David L. Rousso², Caroline A. Pearson², Steven E. Weicksel³, Manuela Melchionda¹, S. Neda Mousavy Gharavy¹, James Briscoe¹*, Bennett G. Novitch^{2,3}*

1 The Francis Crick Institute, London, United Kingdom, **2** Department of Neurobiology, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, California, United States of America, **3** Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, Michigan, United States of America

✉ These authors contributed equally to this work.

* james.briscoe@crick.ac.uk (JB); bnovitch@ucla.edu (BGN)



OPEN ACCESS

Citation: Sagner A, Gaber ZB, Delile J, Kong JH, Rousso DL, Pearson CA, et al. (2018) Olig2 and Hes regulatory dynamics during motor neuron differentiation revealed by single cell transcriptomics. *PLoS Biol* 16(2): e2003127. <https://doi.org/10.1371/journal.pbio.2003127>

Academic Editor: Marianne Bronner, California Institute of Technology, United States of America

Received: May 25, 2017

Accepted: January 5, 2018

Published: February 1, 2018

Copyright: © 2018 Sagner et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: Single cell RNA sequencing data are available via ArrayExpress (<http://www.ebi.ac.uk/arrayexpress/experiments/EMTAB-5466>). All other relevant data has been uploaded as Supporting information files.

Funding: Wellcome Trust (grant number FC001051; WT098326MA). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. EMBO Long-term fellowship (grant number 1438-2013). The funder had no role in

Abstract

During tissue development, multipotent progenitors differentiate into specific cell types in characteristic spatial and temporal patterns. We addressed the mechanism linking progenitor identity and differentiation rate in the neural tube, where motor neuron (MN) progenitors differentiate more rapidly than other progenitors. Using single cell transcriptomics, we defined the transcriptional changes associated with the transition of neural progenitors into MNs. Reconstruction of gene expression dynamics from these data indicate a pivotal role for the MN determinant Olig2 just prior to MN differentiation. Olig2 represses expression of the Notch signaling pathway effectors Hes1 and Hes5. Olig2 repression of Hes5 appears to be direct, via a conserved regulatory element within the Hes5 locus that restricts expression from MN progenitors. These findings reveal a tight coupling between the regulatory networks that control patterning and neuronal differentiation and demonstrate how Olig2 acts as the developmental pacemaker coordinating the spatial and temporal pattern of MN generation.

Author summary

How are the right types of cells produced in the right place, at the right time and in the correct numbers, in a developing tissue? One example of where progress has been made towards answering this question is the embryonic spinal cord. In this tissue, extracellular signals, such as the morphogen sonic hedgehog (Shh), control the pattern of generation of molecularly distinct sets of neural progenitors, from which different classes of motor neurons and interneurons are generated. Motor neurons differentiate at a much higher rate than the adjacent interneurons, and this ensures that more motor neurons than interneurons are generated and in an appropriate temporal sequence. To understand the

study design, data collection and analysis, decision to publish, or preparation of the manuscript. Cancer Research UK (grant number FC001051). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Whitehall Foundation (grant number 2004-05-90-APL). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. March of Dimes Foundation (grant number 5-FY06-7). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NINDS (grant number R01NS053976, R01NS072804, R01NS085227). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. UK Medical Research Council (grant number FC001051). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Human Frontiers Science Program (grant number LT000401/2014-L). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. People Programme (Marie Curie Actions) of the European Union's Seventh Framework Programme (grant number FP7-2013 624973). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Abbreviations: β -Gal, beta-galactosidase; β Glob, beta-globin; bHLH, basic helix-loop-helix; Chat, choline acetyltransferase; ChIP-Seq, chromatin immunoprecipitation-sequence; CHIR, Wnt pathway activator CHIR99021; Cre, bacteriophage P1 Cre recombinase; DBZ, dibenzazepine; Dll1, Delta-like 1; e, embryonic day; E-box, bHLH transcription factor binding site; EGFP, *enhanced green fluorescent protein*; EnR, Engrailed transcriptional repression domain; EP, electroporation; ESC, embryonic stem cell; Fbp7, *fatty-acid binding protein 7*; FGF, fibroblast growth factor 2; FLAG, FLAG epitope tag; FP, floor plate; GFP, green fluorescent protein; GSK3, glycogen-synthase kinase 3; GO, gene ontology; Hes, *Hairy/Enhancer of Split*; HH, *Hamburger-Hamilton*; H5 (e1), *Hes5(e1)* genomic element; IN, interneuron; IRES, internal ribosomal entry site; Isl1, *Islet1*; KSP, K shortest paths; mKate2, monomeric far-red fluorescent protein *Katushka-2*; MN, motor neuron; nEGFP, nuclear EGFP; Ngn2, *Neurogenin 2*; NMP, neuromesodermal progenitor; NLS, nuclear localization signal; NMP, neuromesodermal progenitor; NP, neural progenitor; ns, not

mechanisms responsible for this phenomenon, we investigated the dynamics of the Shh-controlled gene regulatory network operating as motor neurons form from progenitors. We used these data to uncover the accompanying regulatory mechanisms, and this identified two functions for the transcription factor Olig2. First, Olig2 is essential for establishing motor neuron progenitor identity downstream of Shh signaling. Subsequently, Olig2 directly promotes neuronal differentiation in motor neuron progenitors by suppressing the expression of Hes genes, negative regulators of neuronal differentiation. Together, our findings reveal a tight coupling between the genetic networks that control patterning and neuronal differentiation in motor neuron progenitors and thereby explain their characteristic early and rapid rate of neuronal differentiation.

Introduction

The orderly development of embryonic tissues relies on gene regulatory networks that control patterns of gene expression, tissue growth, and cell differentiation [1,2]. Genetic and molecular studies have identified many of the constituents of these networks and have begun to define the regulatory hierarchy between them. Nevertheless, how cell fate assignment is coordinated with proliferation and differentiation remains poorly understood.

An experimentally well-characterized tissue that exemplifies this problem is the vertebrate spinal cord. In ventral regions of the developing spinal cord, proliferating progenitors are exposed to a gradient of sonic hedgehog (Shh) signalling that controls the expression of a set of homeodomain and basic helix-loop-helix (bHLH) transcription factors (TFs) [3–5]. These TFs form a gene regulatory network that progressively allocates progenitor identity, dividing the spinal cord into molecularly discrete domains arrayed along the dorsal-ventral axis [6,7]. This combinatorial transcriptional code determines the subtype identity of the postmitotic neurons generated by progenitors in each domain, thereby controlling the position at which motor neurons (MNs) and interneurons emerge [3,8–10].

Among the first neurons to differentiate in the ventral spinal cord are MNs. In mouse and chick, these are formed over a 2–3-day period [11]. During this time, most if not all MN progenitors exit the cell cycle and differentiate, whereas the adjacent progenitor domains that give rise to interneurons continue to divide and, consequently, differentiate at a much slower pace [11,12]. These differences in differentiation rate play an important role in the elaboration of spinal cord pattern and ensure that appropriate numbers of MNs are generated. This raises the question of how the regulatory mechanisms defining MN progenitors prime these cells to differentiate rapidly.

The induction and differentiation of MNs are characterized by a series of gene expression changes. Initially, Shh signaling induces the bHLH protein oligodendrocyte transcription factor 2 (Olig2), resulting in the repression of the homeodomain protein *Irx3* and bHLH protein *Bhlhb5* (also known as *Bhlhe22*) normally expressed in neural progenitors (NPs) dorsal to MNs [13–16]. Ectopic expression of Olig2 represses both *Irx3* and *Bhlhb5*, resulting in ectopic MN production [13,16,17]. Conversely, in the absence of Olig2, MN generation fails, and instead, *Irx3* and *Bhlhb5* expression are maintained, and NPs differentiate into ventral interneurons [14–16,18].

The gene regulatory mechanisms that are responsible for the higher rate of neurogenesis of MN progenitors compared to other NPs in the spinal cord are not well understood. Whether Olig2 functions as an activator or inhibitor of neurogenesis is also unclear. Initial studies indicated that expression of Olig2 accelerates cell cycle exit [13], and the absence of Olig2 results in

significant; N2, Ngn2 protein; N2B27, N2 and B27 media supplements; Olig2, oligodendrocyte transcription factor 2; O2, Olig2 protein; PKA, protein kinase A; pMN, MN progenitor; p2, V2 interneuron progenitor; p3, V3 interneuron progenitor; RA, retinoic acid; RT-qPCR, real-time quantitative polymerase chain reaction; SAG, Smoothened/Shh signaling agonist; scRNA-seq, single cell RNA sequencing; sgRNA, short guide RNA; Shh, sonic hedgehog; TF, transcription factor; Tubb3, neuronal class III beta-tubulin; T2A, Thosea asigna virus 2A peptide sequence; V2, V2 interneuron; V3, V3 interneuron; WT, wild-type.

a characteristically slower tempo of neuronal differentiation [14]. Olig2 promotes the expression of the proneural bHLH TF Neurogenin 2 (Ngn2), and ectopic expression of Ngn2 causes progenitor cells to exit the cell cycle and prematurely differentiate into neurons [13,17,19–23]. These studies also showed that Olig2 acts as a transcriptional repressor to promote Ngn2 expression [13,17], implying that Olig2 elevates Ngn2 expression by negatively regulating the expression of Ngn2 repressors. Candidate Ngn2 repressors include members of the Hairy/Enhancer of Split (Hes) family of TFs, which act downstream of the Notch signaling pathway to prevent neuronal differentiation and maintain progenitors in a dividing, undifferentiated state [24–26].

Although these studies suggested that Olig2 promotes motor neurogenesis, subsequent studies ascribed antineurogenic and pro-proliferative functions to Olig2 (reviewed in [27]). These conclusions were based on the Olig2-mediated repression of Mnx1 (Hb9), a homeodomain transcription factor expressed by postmitotic MNs [28], and the cell cycle inhibitor p21 [29]. Olig2 also has the capacity to form heterodimers with Ngn2 that inhibit Ngn2's neurogenic activity [28], and oppose the functions of the tumor suppressor protein p53 [30]. Furthermore, addition of Olig2 to TF reprogramming cocktails inhibits conversion of fibroblasts to MNs [31], supporting the idea that Olig2 interferes with the differentiation of MNs. Thus, although the genetic evidence establishes Olig2 as a key determinant of MN identity, these apparently contradictory findings leave unexplained how Olig2 coordinates specification of neuronal identity while determining the rate of differentiation.

Single cell RNA sequencing (scRNA-seq) is emerging as a novel and powerful technology to identify distinct cell types in complex mixtures and to define developmental trajectories during differentiation [32–36]. Here, we took advantage of an in vitro model that allows the generation of ventral spinal cord cell types from embryonic stem cells (ESCs) to perform scRNA-seq analysis of developing NPs [37]. We used these data to reconstruct and validate the differentiation trajectory of MN progenitors and to infer the gene regulatory mechanisms by which Olig2 promotes MN differentiation. Both in vivo and in vitro cells commit to MN differentiation asynchronously. This limits the temporal resolution of conventional gene expression assays, potentially obscuring details of the sequence of events during MN differentiation. Here, we developed a method to reconstruct the differentiation trajectory from scRNA-seq data that provides much greater temporal resolution of the transcriptional dynamics during MN differentiation than previously available. This approach identified a sequence of distinct phases in MN differentiation, including two distinct Olig2 expression states: an initial Olig2^{LOW} state, during which Hes1 expression decreases and Olig2 is coexpressed with Hes5, and a subsequent Olig2^{HIGH} state, in which high levels of Olig2 promote differentiation by repressing Hes5, thereby indirectly inducing Ngn2. We validated this two-phase model using quantitative image analysis of a fluorescent Olig2 reporter and provide in vitro and in vivo evidence that Olig2 acts directly on *Hes* genes to promote cell cycle exit and neurogenesis in the MN progenitor domain (pMN domain). Together, the data provide a comprehensive view of the regulatory network that controls the specification of MN progenitors and identify a molecular mechanism coordinating the specification of positional identity with differentiation.

Results

In vitro generation of MN and V3 interneuron progenitors

To define the sequence of events that leads to the generation of somatic MNs, we took advantage of ESCs, which can be directed to differentiate into spinal NPs in vitro [37]. This method relies on the exposure of ESCs, cultured as a monolayer, to a brief pulse of Wnt signalling prior to neural induction (Fig 1A). This induces the caudalizing TFs Cdx1,2,4 [37]. Subsequently,




Fig 1. Characterization of MN differentiation from ESCs. (A) Scheme outlining the differentiation protocol. ESCs are plated in N2B27 + FGF for 2 days before being exposed to N2B27 + FGF/CHIR, resulting in the production of NMPs at day 3. Cells are subsequently exposed to RA and SAG to promote differentiation into ventral NPs and MNs. (B, C) Expression of NP (*Pax6*, *Olig2*, *Nkx2.2*, *Sox1*) and MN (*Isl1/2*) markers between day 4 and day 7 in differentiating ESCs. (D) RT-qPCR analysis of *Irx3*, *Pax6*, *Nkx6.1*, *Olig2*, and *Nkx2.2* expression from day 3 to day 7 reveals progressive ventralization in response to increasing duration of Shh signaling. Underlying data are provided in [S1 Data](#). (E) MN induction after day 5, revealed by RT-qPCR analysis of *Sox1*, *Ngm2*, *Isl1*, and *Tubb3*. Underlying data are provided in [S1 Data](#). Scale bars = 40 μ m. CHIR, Wnt pathway activator CHIR99021; ESC, embryonic stem cell; FGF, fibroblast growth factor 2; MN, motor neuron; NMP, neuromesodermal progenitor; NP, neural progenitor; N2B27, N2 and B27 media supplements; RA, retinoic acid; RT-qPCR, real-time quantitative polymerase chain reaction; SAG, Smoothened/Shh signalling agonist.

<https://doi.org/10.1371/journal.pbio.2003127.g001>

removal of Wnt signalling and concomitant exposure to retinoic acid (RA) and the Smoothened/Shh signalling agonist (SAG) results in the generation of NPs expressing progenitor markers characteristic for the ventral spinal cord, such as *Olig2* and *Nkx2.2* ([Fig 1B](#)), and MNs expressing postmitotic markers, including *Isl1* (*Isl1*), *Mnx1*, and neuronal class III beta-tubulin (*Tubb3*) ([Fig 1B and 1C](#) and [S1A Fig](#)). These NPs initially express *Hoxb1* and, later, *Hoxb9* ([S1B Fig](#)) and differentiate into *Hoxc6*-positive MNs, characteristic of forelimb level spinal cord MNs ([S1B and S1C Fig](#)) [[37–40](#)].

In vivo NPs respond to both the levels and duration of Shh signalling by transitioning through a succession of progressively more ventral gene expression states ([S2A Fig](#)) [[6,41–43](#)]. To further characterize the behavior of ESC-derived NPs in vitro, we first asked whether treatment of NPs with increasing concentrations of SAG (0, 10, 50, 100, 500, and 1,000 nM SAG) leads to progressively more ventral cell fates. Generation of NPs in the absence of SAG resulted in the expression of *Pax3*, *Pax7*, and *Dbx1*, indicative of a dorsal and intermediate NP identity ([S2B Fig](#)). Treatment with 10 nM SAG resulted in the down-regulation of these genes and induction of the pan-ventral marker *Nkx6.1* ([S2B and S2C Fig](#)). Between 50 and 500 nM SAG, expression of the MN progenitor marker *Olig2* was observed, while treatment with 500 and 1,000 nM SAG resulted in further ventralization and induction of the V3 interneuron progenitor (p3) determinant *Nkx2.2* ([S2B and S2D Fig](#)). Induction of ventral markers coincided with the successive down-regulation of *Irx3* and *Pax6*, consistent with their in vivo expression patterns ([S2B and S2D Fig](#)). Thus, in vitro NPs respond to different levels of Shh pathway activity by induction of the same progenitor markers that demarcate NP domains in the embryonic ventral spinal cord.

We next tested whether in vitro NPs also displayed progressive ventralization in response to increasing exposure durations to a constant concentration of SAG. To this end, we treated cells with 500 nM SAG from day 3 and quantified gene expression by real-time quantitative polymerase chain reaction (RT-qPCR) over the course of the next few days. At day 3.5, 12 hours after the cessation of Wnt signalling and addition of RA and SAG, cells expressed *Sox1*, *Pax6*, and *Irx3*, consistent with the acquisition of NP identity ([Fig 1B and 1D](#)). The absence of ventral markers at this stage indicates that these NPs initially adopt a dorsal/intermediate positional identity [[42,43](#)]. By day 4, the expression of *Pax6* and *Irx3* were maintained and *Nkx6.1*, which is expressed broadly in the ventral third of the neural tube, was induced ([Fig 1B and 1D](#)). Within 12 hours of this time point, *Olig2* expression commenced and both *Pax6* and *Irx3* declined ([Fig 1B–1D](#)). Over the next 48 hours, *Pax6* and *Irx3* were further repressed, *Nkx2.2* increased, and *Olig2* expression began to decline ([Fig 1B–1D](#)). The order in which these genes were activated and repressed closely resembles the temporal-spatial sequence of progenitor domains in the embryonic spinal cord [[6,42,43](#)] and suggests that, under these conditions, MN progenitors are generated in vitro between days 4.5 and 6.

Consistent with the generation of MN progenitors in vitro, *Ngm2* was induced following *Olig2* ([Fig 1E](#)), and with an approximately 12-hour delay, we observed markers characteristic of postmitotic MNs, including *Isl1* and *Tubb3* ([Fig 1C and 1E](#)). Concomitantly, the expression

of the NP marker *Sox1* declined (Fig 1C and 1E). Taken together, these data indicate that this method of directing ESC differentiation recapitulates in vivo dynamics of neural tube patterning between embryonic days (e)8.5 and 10.5, and results in the production of MN progenitors and MNs characteristic of those normally found at forelimb levels.

Single cell transcriptome analysis of in vitro NPs

We reasoned that analyzing the transcriptome of individual cells would provide insight into the transitions in gene expression associated with the differentiation of MNs and allow the construction of a detailed developmental timeline. We therefore performed scRNA-seq analysis using the Fluidigm-C1 platform on 236 cells isolated from day 4 to day 6 of the differentiation protocol. After applying quality filters (see S1 Text), transcriptomes of 202 cells were retained for subsequent analysis (25 cells from day 4, 68 cells from day 5, and 109 cells from day 6). To identify the cell states present in the dataset, we established a data-driven analysis pipeline based on hierarchical clustering and association of gene modules with specific gene ontology (GO) terms (see S1 Text). In brief, the data were first filtered by removing genes that did not exceed a Spearman correlation of $r > 0.4$ with at least two other genes (retaining 2,287 genes). A combination of hierarchical clustering and automated selection criteria identified 22 gene modules that represent distinct patterns of gene expression across the dataset (see S1 Text and S1 Table). Further functional characterization of these gene modules based on GO terms resulted in the identification of 10 gene modules that were sufficient to assign a cell type classification to each cell in the dataset using hierarchical clustering (S3A Fig and S2 Table). Cells in these clusters showed comparable read counts and number of expressed genes per cell, suggesting that these properties did not bias the clustering (S3B Fig).

Consistent with our previous finding that the spinal NPs generated by differentiation of ESCs share a developmental lineage with trunk mesoderm [37], we observed two mesodermal cell populations in our dataset: paraxial presomitic mesoderm characterized by the expression of *Meox1* and *Foxc1* and a vascular endothelial population expressing *Dll4* and *Cdh5* (S3A Fig). The remaining cell clusters corresponded to different stages of NPs and differentiating MNs (Fig 2A). Five gene modules were associated with these cells (comprising 306 genes; see S1 Table). Module 1 was enriched for genes up-regulated in early NPs, including the TF *Irx3*. Module 2 contained genes expressed in MN progenitors, including the ventral progenitor markers *Olig2* and *Nkx6.1* and the neural-specific POU domain TF *Pou3f2* (aka Brn-2). Module 3 comprised a set of genes transiently expressed in MNs as they differentiate, such as the bHLH TFs *Ngn2*, *Neurod1*, *Neurod4*, and *Hes6*; the homeodomain TFs *Isl1* and *Lhx3*; and the Notch ligand *Delta-like 1* (*Dll1*). Modules 4 and 5 revealed two successive waves of neuronal gene induction. Module 4 contained genes induced early in differentiated MNs such as *Tubb3*, the RNA-binding protein *Elavl3* (aka HuC) and the SoxC TF *Sox4*, while Module 5 consisted of genes characteristic of more mature MNs, represented by *choline acetyltransferase* (*Chat*) and the TFs *Isl2* and *Onecut1* [44–47].

Whereas the five cell clusters defined by these modules represented a progressive shift of cell states from early progenitor cells to MNs, the remaining cell cluster exhibited a divergent gene expression signature. In this cluster, many genes contained in Modules 1 and 2 were down-regulated, but neuronal gene expression was not increased. This cluster exclusively consisted of day 6 cells (Fig 2A). *Nkx2.2* could be detected in some cells of this cluster (S3C Fig), suggesting that it was composed of cells progressing from a pMN to a more ventral p3 identity. Further differential gene expression analysis on this population identified *fatty-acid binding protein 7* (*Fabp7*) as enriched in these cells (S3C Fig). *Fabp7* levels are markedly up-regulated in p3 progenitors in vitro and at cervical and brachial levels in embryonic spinal cords at e10.5




Fig 2. Reconstruction of transcriptional changes during MN differentiation. (A) Identification of NP cell states using hierarchical clustering of gene expression profiles of the individual cells. (B) Cell state graph constructed from minimum spanning trees, color coded for the cell populations identified in Fig 2A. Stars indicate start and end cells for the reconstruction of transcriptional changes along pseudotime. Shading of edges between cells indicates how often the edge was used in the reconstruction of gene expression along pseudotime (see S1 Text). (C) Cell state graph color coded for expression levels of *Irx3*, *Olig2*, *Ngn2*, *Lhx3*, *Isl1*, and *Chat*. (D) Inferred changes in gene expression over pseudotime from 9,000 shortest paths connecting start and end cells (stars in B). Each shortest path was resampled to a length of 41 pseudo-time points to enable statistical measurements of gene expression. Cell IDs are color coded according to cell states in (A). Quantification of the global rate of change in gene expression identifies three metastable states (light gray)

separated by transition states, during which the rate of change in gene expression is increased (dark gray). Transition phases are defined as intervals along the pseudo-temporal timeline at which the second derivative of the global gene variation is negative, while metastable states are characterized by a positive second derivative. (E) Gene expression profiles along pseudo-time for NP TFs (*Irx3*, *Pax6*, *Nkx6.1*, and *Olig2*), genes associated with the transition to MNs (*Ngn2*, *Lhx3*, and *Neurod4*) and MN markers (*Isl1/2*, *Tubb3*, and *Chat*). (F) Levels of gene expression for *Hes1/5*, *Olig2*, and *Ngn2* over pseudotime. Note that *Olig2* expression appears biphasic, with up-regulation of *Olig2* concomitant to *Ngn2* induction and repression of *Hes1/5* in the transition phase from NP to MN. *Chat*, choline acetyltransferase; KSP, K shortest paths; MN, motor neuron; NP, neural progenitor; pMN, MN progenitor; p3, V3 interneuron progenitor; *Tubb3*, neuronal class III beta-tubulin.

<https://doi.org/10.1371/journal.pbio.2003127.g002>

(S3D Fig). We therefore conclude that this cluster contains cells progressing from MN to p3 progenitors. Taken together, this suggests our scRNA-seq analysis identifies cells along the MN developmental timeline and partitions these into specific cell types from early NPs to post-mitotic MNs and p3 progenitors.

We next asked whether it was possible to reconstruct the developmental timeline from the transcriptome data. For this, we used the 306 genes contained in the five neural gene modules to visualize the developmental trajectory as a pseudo-temporal ordering derived from a consensus of a large number of randomized minimum spanning trees (see S1 Text). The resulting cell graph represents the predicted developmental order of cells based on their transcriptome profile and, hence, differentiation state (Fig 2B). Strikingly, the five previously characterized cell clusters were ordered on the cell state graphs as expected from the characterization of their gene expression profile (Fig 2C). The graph revealed developmental trajectories originating from *Irx3* expressing early NPs to MN progenitors characterized by *Olig2* expression (Fig 2C). These progenitors then differentiated into MNs via the sequential expression of *Ngn2*, *Lhx3*, *Isl1*, and *Chat* (Fig 2C) or into p3 progenitors characterized by *Nkx2.2* and *Fabp7* expression (S3C Fig). To investigate these trajectories in more detail, we focused on the developmental trajectory leading from NPs to MNs. To represent changes in gene expression in an unbiased manner, we reconstructed the average gene expression program along pseudotime from the 9,000 shortest paths connecting *Irx3*-expressing progenitor cells to differentiated MNs on the cell state graph (starred cells in Fig 2B, see S1 Text). Each individual path was resampled to a constant length of 41 pseudotime points (Fig 2D), allowing statistical measurements along the developmental timelines. The outcome was predicted gene expression dynamics during MN differentiation.

Characterization of transcriptional changes during MN differentiation

As a first validation, we asked if the pseudo-temporal ordering reproduced the temporal sequence of well-characterized gene expression changes that lead to MN differentiation. The inferred trajectory correctly predicted the induction sequence of the homeodomain and bHLH TFs *Irx3*, *Pax6*, *Nkx6.1*, and *Olig2* involved in ventral patterning of the spinal cord (Fig 2E) [41–43]. Next, we focused on the transition from progenitors to MNs. As expected, this transition was associated with the transient expression of *Ngn2*, *Neurod4*, and *Lhx3*, followed by the expression of MN markers, including *Isl1/2*, *Tubb3*, and *Chat* (Fig 2E). To assess the robustness of these gene expression dynamics, we utilized a bootstrapping approach to ask how dependent these are on individual cells with particular gene expression values (see S1 Text). A total of 1,000 bootstrapped datasets were constructed by randomly drawing cells, with replacement, while maintaining original sample size. Then, expression profiles were calculated for each gene in each replicate (S4 Fig). To statistically quantify their robustness, we asked how well these profiles were correlated between each pair of replicates (see S1 Text). This analysis revealed a mean Spearman correlation value greater than 0.85 for most genes (S4 Fig). This suggests that the observed gene expression dynamics do not depend on the levels of gene expression in specific cells along the pseudo-temporal trajectory and are a robust representation of the gene expression dynamics during MN differentiation.

The process of cell development has been characterized as a series of metastable states defined by a relatively homogenous gene expression program connected by stereotypic transitions [48]. During these transitions, coordinated changes in gene expression occur, often induced in response to a change in signalling. We reasoned that metastable states and transition phases should be evident in the pseudo-temporal ordering. Quantifying the variation in gene expression by averaging the normalized derivative of the most dispersed genes' expression profiles identified these phases (Fig 2D). The three metastable states in which gene expression changes were relatively modest corresponded to early NPs, MN progenitors, and MNs. Linking these states were transitions characterized by an increased change in the global gene expression profile. The first transition corresponded to the switch from *Irx3*-expressing intermediate progenitors to *Olig2*-expressing MN progenitors (Fig 2E), while the second captured the transition of progenitors to postmitotic neurons (Fig 2E).

We asked whether signatures of signalling pathways driving these transitions could be identified. To this end, we examined the induction and disappearance of canonical target genes for different signalling pathways. As expected, the transition from *Irx3* to *Olig2* coincided with the induction of well-known Shh target genes *Ptch2*, *Hhip1*, and *Gli1*, consistent with Shh signalling mediating this transition (S3E Fig). By contrast, the second transition was accompanied by a loss of Notch signalling, marked by the disappearance of *Hes1/5* and induction of markers causing or characteristic of a loss of Notch signalling, including *Numbl*, *Hes6*, *Dll1*, *Ngn2*, and *Neurod4* (Fig 2E and S3F Fig). Strikingly, the beginning of this stage coincided with peak expression levels of *Olig2* (Fig 2E and 2F). This finding raised the possibility that high levels of *Olig2* promote neurogenesis, potentially by directly regulating levels of Notch signalling. In summary, the characterization of changes in the transcriptional profile in pseudotime identified distinct metastable cell states and the signalling pathways associated with the transitions between these states.

In vitro and in vivo validation of the pseudo-temporal ordering

To extend this approach and validate the predicted timeline, we asked whether the data were sufficient to capture fine-grained temporal information that could be tested experimentally. Examination of the transition from *Olig2*-expressing progenitors to *Isl1*-expressing MNs predicted the transient expression of first *Ngn2*, then *Lhx3*, and finally *Isl1* (Fig 2C and 2E). This is consistent with in vivo data indicating that *Lhx3* precedes the expression of other MN markers in the spinal cord [47,49], and a similar sequence of gene expression has been described in an in vitro MN differentiation protocol based on embryoid bodies [45,50]. To confirm this sequence of events in vitro, we assayed *Olig2*, *Ngn2*, *Lhx3*, and *Isl1* on day 6 of differentiation and quantified the levels of expression in individual nuclei (S5A Fig). Comparison of *Olig2* and *Isl1* levels in individual nuclei revealed a clear trajectory from *Olig2*-positive, *Isl1*-negative NPs to *Isl1*-positive, *Olig2*-negative MNs. Overlaying the levels of *Ngn2* and *Lhx3* in the same cells revealed that both proteins are only transiently expressed along the differentiation trajectory (S5B and S5C Fig). To confirm the absence of *Lhx3* in more mature MNs, we assayed *Lhx3*, *Isl1*, and the pan-neuronal marker *Tubb3* (S5D Fig). Consistent with the pseudo-temporal ordering, most *Tubb3*-expressing cells displayed high levels of *Isl1* expression but only low levels of *Lhx3*, while cells with high levels of *Lhx3* did not express high levels of *Isl1* or *Tubb3* (S5D Fig). In summary, these two observations confirm the predictions from the pseudo-temporal ordering and validate the approach for predicting fine-grained changes in the transcriptional program of cells along the differentiation trajectory to MNs.

To further test the reliability of the timeline and demonstrate the validity of the approach for understanding MN differentiation dynamics, we asked if we could predict novel genes

involved in MN formation. To this end, we selected genes positively correlated with *Olig2* and *Ngn2* (S5E and S5F Fig). One gene with a particularly strong relationship was *Zbtb18* (also known as *RP58* or *Zfp238*). *Zbtb18* is a zinc-finger TF with a BTB domain. In the brain, its loss causes microcephaly and decreased neuronal and increased glial differentiation [51]. Less is known about its expression pattern and role in the spinal cord, although in situ hybridization analyses have suggested it is predominantly expressed in ventral progenitors [52]. As expected, when we assayed *Zbtb18* using immunohistochemistry, it was expressed in cells that also expressed *Olig2* and *Ngn2* (S5G–S5I Fig). Consistent with this, its expression was detected in vivo in the pMN domain at e9.5 in cells that also expressed high levels of *Olig2* and *Ngn2* (S5J Fig). At e10.5, it was still predominantly expressed ventrally, although no longer confined to the pMN domain (S5K Fig). In summary, this expression pattern further validates the computationally reconstructed MN differentiation timeline.

Olig2 expression increases as cells commit to MN differentiation

The MN differentiation timeline indicated that *Olig2* expression was induced as *Irx3* was repressed (Fig 2E), consistent with the cross-repressive interactions between these two genes [13,17,53]. This transition demarcated the transition from the first to the second phase identified in the MN timeline. It was noticeable that the expression of *Olig2* appeared biphasic with a marked increase in levels of *Olig2*, which coincided with the transition from the second to the third phase. Moreover, this transition corresponded to the induction of *Ngn2*. This predicted that *Olig2* levels peak at the onset of differentiation before being down-regulated as MN identity is elaborated (Fig 2E). To test this prediction, we first examined the levels of *Olig2* and *Ngn2* in the neural tube of e9.5 and e10.5 embryos during the period of MN production (Fig 3A–3D’). Consistent with previous studies, we found that at both stages, a proportion of *Olig2*-expressing cells also expressed *Ngn2*, while a much lower proportion of cells expressed *Ngn2* outside the pMN domain [13,17,19]. To test if the levels of *Olig2* expression varied in the way predicted by the scRNA-seq data, we quantified levels of *Olig2*, *Ngn2*, and the MN marker *Mnx1* in nuclei of the pMN domain (Fig 3E–3H). This revealed a striking correlation between *Olig2* and *Ngn2* protein levels in individual cells throughout the pMN domain (Fig 3E and 3G). Moreover, cells expressing high levels of *Olig2* and *Ngn2* were differentiating into MNs, as measured by the induction of *Mnx1* (Fig 3H). This quantification also indicated that *Olig2* protein persisted longer than *Ngn2* in MNs, as cells coexpressing high levels of *Olig2* and *Mnx1*, but not *Ngn2*, were observed (Fig 3H). Taken together, these data suggest that high levels of *Olig2* correspond to the induction of *Ngn2* and the onset of neurogenesis within the pMN domain.

These data prompted us to test directly whether progenitors that expressed high levels of *Olig2* were committed to MN differentiation. Since endogenous *Olig2* protein disappears rapidly from differentiated MNs, we took advantage of an ESC line in which we fused monomeric far-red fluorescent protein Katushka-2 (mKate2) to the C-terminus of endogenous *Olig2* via a self-cleaving peptide (Fig 4A) [54,55]. In these cells, the expression of mKate2 provides a read-out of *Olig2* levels, but the increased stability of the fluorescent protein offers a way to mark the progeny of *Olig2*-expressing cells and estimate *Olig2* levels in the progenitor. Control ESC differentiations indicated that *Olig2* expression dynamics, protein levels, and MN formation were similar in cells containing the engineered or wild-type *Olig2* allele (Fig 4B and S6A–S6C Fig). Quantification of the mKate2 and *Olig2* protein levels in individual nuclei revealed a positive correlation in most cells (Fig 4C–4C’ and 4G and S6D–S6F Fig). However, we noted a cohort of cells with much higher levels of mKate2 relative to *Olig2*. Assaying *Isl1/2* expression revealed that these cells were MNs (Fig 4D–4D’). Consistent with this, high levels of *Isl1/2* and




Fig 3. Olig2 expression is higher in Ngn2-expressing progenitors in the pMN domain. (A–B'') Staining for Ngn2 (A, B) and Olig2 (A', B') merged with Mnx1 (green in A'', B'') in spinal cords at e9.5 (A–A'') and e10.5 (B–B''). (C–D'') Higher magnification images of the spinal cords shown in (A–B''). Red arrowheads indicate nuclei with elevated levels of Ngn2 and Olig2. (E, G) Positive correlation between Olig2 and Ngn2 protein levels in individual nuclei at e9.5 (E) ($n = 464$ nuclei) and e10.5 (G) ($n = 1,078$ nuclei). Underlying data are provided in [S1 Data](#). (F, H) Levels of Olig2, Mnx1, and Ngn2 in individual nuclei throughout the pMN domain at e9.5 (F) and e10.5 (H). Plotting Olig2 versus Mnx1 protein levels reveals a clear differentiation trajectory from Olig2-positive pMN cells to Mnx1-positive MNs. Note that high levels of Ngn2 are only observed in cells with high levels of Olig2 expression. In addition, Olig2 protein perdures much longer in Mnx1-positive MNs than Ngn2. Underlying data are provided in [S1 Data](#). Scale bars = 50 μ m. e, embryonic day; MN, motor neuron; pMN, MN progenitor.

<https://doi.org/10.1371/journal.pbio.2003127.g003>

Tubb3 expression were only detected in cells with high levels of mKate2 (Fig 4H and S6A–S6C Fig). Moreover, mKate2 levels negatively correlated with levels of the NP marker Sox1 (Fig 4E–4E'' and 4I). Thus, MNs indeed progress through a distinct Olig2^{HIGH} state as they exit from the NP state.

To address whether the transient up-regulation of Olig2 expression was specific for the transition from pMN cells to MNs, we quantified levels of mKate2 in Nkx2.2-expressing p3 progenitors (Fig 4F–4F''). During development, these progenitors transit through an Olig2-expressing pMN intermediate state before losing Olig2 expression and inducing Nkx2.2 [41,42,56]. In contrast to the positive correlation between Isl1/2 and mKate2 (Fig 4H), cells expressing high levels of Nkx2.2 had low or undetectable levels of mKate2 expression (Fig 4J and S6F Fig). Thus, distinct Olig2 expression dynamics underlie the progression of pMN cells to MNs and p3 progenitors.

Inhibiting Notch signaling increases Olig2 expression

These observations raise the question of what up-regulates Olig2 prior to MN formation. The Notch signalling pathway is implicated in controlling the rate of neurogenesis, and inhibition of Notch signalling in NPs is well known to trigger neuronal differentiation [25,57–59].




Fig 4. Quantification of a fluorescent Olig2 reporter reveals a marked up-regulation of Olig2 prior to MN differentiation. (A) Design of the Olig2-mKate2 reporter. A 3xNLS-FLAG-mKate2 reporter was fused to the C-terminus of endogenous Olig2 via a T2A self-cleaving peptide. (B) Western blot analysis reveals that the targeted allele shows the same expression dynamics and levels as endogenous Olig2. The targeted allele runs at slightly increased molecular weight due to addition of the T2A peptide (see A). Note that both alleles are targeted in this cell line and, consequently, no protein of wild-type size was detected. (C–F'') Immunofluorescence for mKate2 with Olig2 (C–C''), Isl1/2 (D–D''), Sox1 (E–E''), and Nkx2.2 (F–F'') at day 6 of the differentiations. (G–J) Quantification of protein levels of mKate2 and Olig2 (G, $n = 2,851$ nuclei), Isl1/2 (H, same dataset as G), Sox1 (I, $n = 2,049$ nuclei) and Nkx2.2 (J, $n = 2,034$ nuclei) in individual nuclei. Note the positive correlation between mKate2 and Olig2 and Isl1/2, and the negative correlation between mKate2 and Sox1 and Nkx2.2. Underlying data are provided in [S1 Data](#). (K) Inhibition of Notch signaling using 10 ng/μl DBZ causes an increase of neurogenesis. Immunofluorescent staining for Olig2, mKate2, and Tubb3 in control or after 24 hours DBZ treatment at day 6 of the differentiation. (L) Frequency plots of mKate2 fluorescence intensity obtained by flow cytometry reveal a strong increase in the number of mKate2^{HIGH} cells after 24 hours DBZ treatment. Scale bars = 25 μm. DBZ, dibenzazepine; FLAG, FLAG epitope tag; mKate2, monomeric far-red fluorescent protein Katashka-2; MN, motor neuron; Tubb3, neuronal class III beta-tubulin; T2A, Thosea asigna virus 2A peptide sequence; 3xNLS, 3 copies of a nuclear localization sequence peptide.

<https://doi.org/10.1371/journal.pbio.2003127.g004>

Furthermore, the inferred MN differentiation trajectory indicated that two canonical effectors of the Notch pathway, Hes1 and Hes5, decreased as cells switched from the early phase of Olig2^{LOW} expression to Olig2^{HIGH}. We therefore tested whether inhibiting Notch signalling up-regulated Olig2. As expected, inhibition of Notch signalling through the addition of the γ -secretase inhibitor dibenzazepine (DBZ) for 24 hours between day 5 and day 6 of differentiation caused a substantial increase in the number of neurons observed ([Fig 4K](#), compare [S6C](#) and [S6I Fig](#)). Quantifying mKate2 levels using flow cytometry revealed a similarly substantial increase in the number of cells expressing high levels of mKate2 ([Fig 4L](#) and [S6G Fig](#)). Furthermore, co-staining these cells with the pan-neuronal marker Tubb3 revealed that most of the mKate2^{HIGH} cells were neurons ([S6I Fig](#)). To test whether the increase in mKate2 fluorescence is due to increased Olig2 expression upon Notch inhibition, we quantified mRNA levels of *Olig2* and other progenitor and neuronal markers using RT-qPCR after 0, 12, and 24 hours of Notch inhibition ([S6J–S6L Fig](#)). In contrast to other progenitor markers (*Hes1/5*, *Sox2*, *Pax6*), which decreased upon Notch inhibition ([S6J Fig](#)), *Olig2* levels peaked at 12 hours before decreasing after 24 hours ([S6K Fig](#)). The observed *Olig2* expression dynamics are strikingly similar to those of other genes previously implicated in MN formation, including *Ngn2* and *Pou3f2* ([S6K Fig](#)). Consistent with the increase in the expression of neurogenic markers after 12 hours, we also observed an increase in the expression of neuronal genes 12 hours and 24 hours after Notch inhibition ([S6L Fig](#)). Taken together, these data suggest that Notch signalling controls the transition between the distinct phases of *Olig2* expression by restraining *Olig2* expression in MN progenitors.

Olig2 represses the expression of *Hes1/Hes5*

To test whether the up-regulation of Olig2 coincided with the down-regulation of Hes1 and Hes5 in vivo, we examined the expression of these proteins in mouse embryos. Hes1 is broadly expressed by dorsal progenitors that express the homeodomain protein Pax3, as well as floor plate and p3 cells, marked by the expression of Foxa2 and Nkx2.2, respectively ([Fig 5B](#), [5C](#), [5F](#) and [5G](#)) [60]. By contrast, Hes5 is expressed by cells in the intermediate spinal cord, marked by the expression of Irx3 and Pax6 ([Fig 5B](#), [5D](#) and [5E](#)). Olig2 expression was first detectable at e8.5, a time at which Hes5 was broadly expressed throughout the ventral neural tube ([Fig 5M](#)). Shortly thereafter, Olig2 and Hes5 showed a high degree of coexpression, which coincided with an increase in the number of Olig2-expressing MN progenitors ([Fig 5N–5O](#)). However, coexpression of Olig2 and Hes5 appeared to be transient, as by e9.5, Hes5 was down-regulated in many Olig2+ cells, particularly at rostral levels ([Fig 5P](#)), and few coexpressing cells could be found by e10.5 ([Fig 5Q](#)). During this time, Hes1 expression was low or absent in most MN progenitors ([Fig 5H–5L](#)). The progressive decrease in Hes5 expression from Olig2+ cells was mirrored by a reciprocal increase in *Ngn2* expression and, subsequently, the exit of these cells




Fig 5. Olig2 and Hes are dynamically expressed in the mouse neural tube. (A–D) Expression patterns of Ngn2 (green in A), Olig2 (red in A, C, D), Hes1 (red in B, green in C), and Hes5 (green in B, D) in the neural tube at e10.5. Note the low expression levels of Hes1/5 and high expression levels of Ngn2 in the pMN domain (compare A, B). (E) Hes5 (green) expression coincides with the expression of high levels of Pax6 (red) in the intermediate neural tube. (F, G) Hes1 expression (green) is readily detected in both Nkx2.2⁺ p3 progenitors (red in F) and floor plate cells labelled by Foxa2 expression (red in G). (H–Q') Time course of Olig2 (blue), Hes1 (red), Hes5 (red), and Ngn2 (green) expression in neural tubes between e8.5 and e10.5. Multiple panels shown for e9.5 reflect developmental progression from caudal to rostral positions along the neuraxis. Hes1 expression appears to recede from the ventral neural tube upon the onset of Olig2 expression at e8.5 (H) and is thereafter absent from most Olig2⁺ cells (I–L). Olig2 and Hes5 are initially coexpressed (M, N). Over time, Hes5 expression progressively disappears from the pMN domain (N–Q), and Ngn2 concomitantly increases (N'–Q'). Insets show single channel images of the outlined area for the respective markers. Scale bars = 50 μm. e, embryonic day; pMN, MN progenitor; p3, V3 interneuron progenitor.

<https://doi.org/10.1371/journal.pbio.2003127.g005>

from the cell cycle and the onset of MN differentiation marker expression (Fig 5M'–5Q', [13,17,28]). Thus, the transient coexpression of Olig2 and Hes5 in vivo marks the pMN state, while the clearance of Hes5 from Olig2-positive cells coincided with the onset of Ngn2 expression and MN differentiation.

We next asked whether Olig2 might be responsible for the repression of *Hes1* and *Hes5* using *Olig2^{Cre}* knock-in mice [56,61]. In these mice, the Olig2 coding sequence has been replaced with bacteriophage P1 Cre recombinase (Cre) [56]. Thus, Cre protein expression demarcates the presumptive pMN domain in heterozygous control and in homozygous *Olig2^{Cre/Cre}* mutant embryos, which entirely lack Olig2 activity (Fig 6A and 6E). In controls, the pMN domain was flanked dorsally and ventrally by Hes5 and Hes1 expression, respectively, with little overlap of Cre with either protein (Fig 6C–6D' and 6I). By contrast, *Olig2* mutant spinal cords displayed a marked dorsal expansion of Hes1 and ventral expansion of Hes5 into the pMN domain, such that their expression domains appeared to contact one another (Fig 6G–6I). This juxtaposition was associated with a substantial decrease in the number of cells expressing Ngn2 in the pMN domain (Fig 6B, 6F and 6I). Thus, Olig2 is required to maintain the boundaries of Hes1 and Hes5 and allow Ngn2 to accumulate within MN progenitors.

To address whether Olig2 expression was sufficient to repress *Hes1* and *Hes5*, we used in ovo electroporation to deliver retroviral expression constructs driving the expression of a myc epitope-tagged form of OLIG2 into the developing spinal cord of Hamburger-Hamilton (HH) stage 11–13 chick embryos. These conditions have been previously shown to increase *NGN2* expression [13]. Whereas mammals have a single *Hes5* gene, birds contain three *Hes5* paralogs, termed *HES5-1*, *HES5-2*, and *HES5-3* [62], clustered at a common genomic locus (Fig 7A). When Olig2 was misexpressed, all three chick *HES5* genes were substantially reduced, as was the chick *Hes1*-related gene *HAIRY1* (Fig 6J–6N). Similar results were achieved with the misexpression of a dominant repressor form of OLIG2 containing its bHLH DNA-binding domain fused to a heterologous Engrailed transcriptional repression domain (Fig 6O–6S; [13]). Based on these results, we conclude that Olig2 expression suffices to repress *Hes* gene expression in NPs.

Hes proteins and proneural bHLH TFs such as Ngn2 act antagonistically in multiple developmental contexts [25,26], and ectopic Olig2 expression has been shown to promote Ngn2 expression [13]. Two sequences of events could explain the repression of *Hes* genes and induction of Ngn2 in MN progenitors. Either Olig2 represses *Hes1/5* and thereby indirectly induces Ngn2 or, alternatively, Olig2 induces Ngn2, which then antagonizes the expression of the Notch effectors. To distinguish between these possibilities, we investigated if Olig2 represses *Hes5* in *Ngn2* null mutants (S7A–S7F' Fig). To this end, we utilized a *Ngn2* knock-in GFP (*Ngn2^{KIGFP}*) mouse line, in which an internal ribosome entry sequence-Green Fluorescent Protein (IRES-GFP) construct has been inserted into the coding sequence of *Ngn2* [64]. Assays at e9.5 and e10.25 revealed that Olig2 expression was maintained (S7A'–S7F' Fig) and Hes5 repressed in MN progenitors lacking Ngn2 (S7A''–S7F'' Fig). Consistent with the observed repression of *Hes5*, GFP expression from the endogenous *Ngn2* locus was strongly elevated in MN progenitors (S7C–S7F Fig). We therefore conclude that Olig2, not Ngn2, is the main repressor of *Hes* genes in MN progenitors.

These findings raise the question of how important the Olig2-mediated repression of *Hes* genes is for the pattern of neurogenesis in the ventral spinal cord. To address this, we investigated the consequences of preventing Olig2-mediated repression by ectopically expressing chick *HES5-2*, an ortholog of murine *Hes5*, in the ventral spinal cord of chick embryos. Ectopic *HES5-2* expression did not have a noticeable effect on the levels of the progenitor markers SOX2, NKX6.1, PAX6, and OLIG2 (S7G–S7J Fig). By contrast, and consistent with the well-known antineurogenic role of Hes proteins [24,60,65], ectopic *HES5-2* resulted in the down-




Fig 6. Repression of Hes1/5 in the pMN domain depends on Olig2 activity. (A–D) Expression of Cre (green in A–D), Olig2 (red in A), Ngn2 (red in B), Hes1 (red in C, grey in C'), and Hes5 (red in D, grey in D') in e10.5 *Olig2^{Cre/+}* heterozygous embryos. (E–H) In *Olig2^{Cre/Cre}* homozygous mutants, Hes1 expands dorsally (G, G') and Hes5 ventrally (H, H') into the pMN domain, marked by Cre expressed from the *Olig2* locus. The expansion of Hes1/5 coincides with a loss of the high levels of Ngn2 normally seen in the pMN domain. (I) Quantification of Hes1, Hes5, and Ngn2 expression in *Olig2^{Cre/+}* heterozygous and homozygous embryos. The overlap between Cre and Hes1/5 significantly increases in *Olig2^{Cre/Cre}* homozygotes, while overlap between Ngn2 and Cre is strongly reduced. Plot shows the mean \pm SEM from multiple sections collected from 3–5 embryos for each group. Each section is represented by a single dot, with $n = 8–11$ for each group. Underlying data are provided in [S1 Data](#). **** $p < 0.0001$, unpaired t test. (J–S) Electroporation of myc-tagged OLIG2 and an OLIG2-bHLH-Engrailed repressor domain fusion protein in chick neural tubes represses expression of the Hes5 homologues *HES5-1*–*HES5-3* (K–M; Q–R) and the Hes1 homologue *HAIRY1* (N, S). "+" indicates transfected side of the spinal cords. Results are representative of >5 successfully transfected embryos collected from two or more experiments. Scale bars = 50 μ m. bHLH, basic helix-loop-helix DNA binding domain; Cre, bacteriophage P1 Cre recombinase; e, embryonic day; EnR, Engrailed transcriptional repression domain; EP, electroporation; pMN, MN progenitor.

<https://doi.org/10.1371/journal.pbio.2003127.g006>




Fig 7. Olig2 binds to an evolutionarily conserved element near Hes5. (A) Identification of an evolutionarily conserved element containing an E-box in the vicinity of the *Hes5* genomic locus in chick, mouse, and human (*Hes5*(e1)). (B) Analysis of Olig2 ChIP-Seq data from [63] reveals Olig2 binding sites in the vicinity of the *Hes1* and *Hes5* genes. The peak corresponding to the *Hes5*(e1) element is highlighted in red. (C) Electrophoretic mobility shift assays show that both Olig2 and E12 homodimers can individually bind to the *Hes5*(e1) E-box and do not form any heterodimeric complexes (lanes 1–4). Positions of the different protein complexes are indicated by colored arrows. Binding depends on the E-box, as both proteins fail to bind probes containing an E-box mutation (*Hes5*(e1ΔE)) (lanes 5–7). Olig2 binding to *Hes5*(e1) can be abolished by the addition of unlabelled *Hes5*(e1) probes, but not those containing the E-box mutation (lanes 8–14). (D) Id1 inhibits binding of E12, but not of Olig2 or Ngn2, to the *Hes5*(e1) element. Olig2, E12, and Ngn2 alone or Ngn2/E12 heterodimers can bind the *Hes5*(e1) element. Mixing Olig2 or Ngn2 with Id1 does not inhibit their homodimeric binding activities (lanes 2, 5, 8, and 10). In contrast, Id1 strongly inhibits binding of both E12/E12 and Ngn2/E12 complexes (lanes 6 and 10). The addition of E12 without and with Id1 does not affect Olig2 binding efficiency (lanes 2, 4, and 7). ATG, translational initiation codon; ChIP-Seq, chromatin immunoprecipitation-sequence; E-box, bHLH transcription factor binding site; N2, Ngn2 protein; O2, Olig2 protein.

<https://doi.org/10.1371/journal.pbio.2003127.g007>

regulation of the proneuronal TFs NGN2 and NEUROD4 and of the pan-neuronal marker NEUN (S7K–S7Q Fig). Of note, cells that maintained NGN2 and NEUROD4 in these experiments usually contained little if any GFP, marking transfected cells, suggesting they were not electroporated (S7N and S7O Fig). Consistent with this, only a minor fraction of GFP-electroporated cells left the ventricular zone and activated NEUN expression (compare S7M and S7P

Fig). These results suggest that the repression of *Hes* genes is the key mechanism by which Olig2 promotes neurogenesis and that the antineurogenic function of Hes proteins needs to be overcome before *Ngn2* can be induced and neurogenesis initiated. Together, these data indicate that Olig2 plays a critical role in repressing the expression of *Hes* genes within MN progenitors to promote the expression of proneurogenic bHLH TFs, such as *Ngn2* and *Neurod4*, and thereby increases the rate of neuronal differentiation in MN progenitors.

Olig2 acts directly on a *Hes5* regulatory element

The striking effects of Olig2 on *Hes1* and *Hes5* expression prompted us to ask whether Olig2 might directly regulate these genes. Examination of chromatin immunoprecipitation data from mouse NPs revealed several prominent binding sites of Olig2 in the vicinity of the two loci (Fig 7B) ([63], <http://www.ebi.ac.uk/ena/data/view/ERX628418>). Furthermore, some of these binding sites are in close proximity to previously mapped binding sites for the Notch signalling cofactor RBPJ [66]. Bound regions included sites close to the transcription start sites of the genes and in putative distal regulatory elements (Fig 7B). Aligning genomic sequences of the *Hes5* locus from chick, mouse, and human indicated that one of the binding sites for Olig2 and RBPJ coincided with a highly conserved, approximately 200–base pair element, hereafter termed Hes5(e1), that is 80% identical between mouse and human and 53% identical between chick and mouse (Fig 7A and 7B). This element is 7.9 kilobases (kb) 5' to the transcriptional start site for *Hes5* in mouse, 10.5 kb 5' to the transcriptional start site in human, and in the middle of the *HES5* gene cluster in chick.

Like many bHLH proteins, Olig2 binds to canonical bHLH transcription factor binding site (E-box) DNA response elements with the palindromic sequence CANNTG [28]. This motif was found within the most conserved central region of the Hes5(e1) element (87% identity between chick and mouse over 46 bp; 98% identity between mouse and human) (Fig 7A). To confirm that Olig2 could bind to the Hes5(e1) element, we performed in vitro binding experiments using a probe comprising the conserved central region. In vitro translated Olig2 readily bound to the Hes5(e1) E-box, as did other bHLH proteins such as E12 and *Ngn2* (Fig 7C and 7D). These binding activities were abolished when the conserved E-box sequence was mutated (Fig 7C). To test if Olig2 binding activity is enhanced by the presence of E proteins, we mixed Olig2 protein with E12 but found no evidence of either an Olig2:E12:DNA complex or enhanced binding affinity to the Hes5(e1) E-box (Fig 7C). In addition, mixing Olig2 with Id1, a potent competitor for E protein binding, did not diminish Olig2 binding, although mixing E12 and *Ngn2* with Id1 completely abolished both E12/E12 and *Ngn2*/E12 binding activities (Fig 7D). The binding of both Olig2 and *Ngn2* to Hes5(e1) in vivo was further confirmed through chromatin immunoprecipitation experiments (S8A Fig). Taken together, these data indicate that Olig2 homodimers bind directly to a highly conserved Hes5(e1) regulatory element through a single E-box site that may be targeted by other bHLH proteins.

The Hes5(e1) element restricts gene expression from the pMN

The observation that Olig2 could bind to the conserved element within the *Hes5* locus prompted us to test whether this element restricted gene expression selectively from the pMN domain. To test this, we generated reporter constructs consisting of Hes5(e1), with or without an intact E-box, upstream of a β -globin minimal promoter driving expression of a nuclear enhanced GFP gene (*Hes5*(e1)- β G::nEGFP) (Fig 8C). We co-electroporated these constructs into the chick spinal cord, together with a plasmid encoding nuclear β -galactosidase (β gal) driven by the CMV/ β -actin promoter (Fig 8A, 8B, 8D and 8E). β gal expression appeared to be uniform throughout the dorsal-ventral axis of the neural tube (Fig 8A, 8D and 8F). By contrast,




Fig 8. The Hes5(e1) element is required for repression of reporter genes in the pMN domain. (A, B) Co-electroporation of CMV/β-actin::nLacZ and Hes5(e1) reporter plasmids into chick spinal cord. Although electroporation (revealed by β-Gal antibody staining, magenta in [A]) is uniform along the dorsal-ventral axis, expression of the EGFP reporter is confined to intermediate parts of the neural tube (A, B), and little coexpression of Olig2 and EGFP was detected (B). (C) Design of Hes5(e1) and Hes5(e1ΔE) reporters. The Hes5(e1) element was cloned in front of β-globin minimal promoter to drive EGFP reporter gene expression. To test the importance of the E-box in the Hes5(e1) element, critical base pairs for Olig2 binding were mutated (red). (D, E) Co-electroporation of CMV/β-actin::nLacZ and Hes5(e1ΔE) reporter plasmids into chick spinal cord. In contrast to the Hes5(e1) reporter plasmid, significant coexpression of Olig2 and GFP in the pMN domain is detected (E). Note that E-box mutation reduced the basal activity of the reporter such that longer exposure times were needed to achieve the signal levels seen

in the intermediate spinal cord with the nonmutated Hes5(e1) reporter (S8B and S8C Fig). (F) Scatter dot plots display the dorsal-ventral positions (distance from the roof plate) of individual cells expressing the Hes5(e1) and Hes5(e1ΔE) reporters, relative to CMV/β-actin::nLacZ and Olig2. Results are aggregated from five representative sections taken from five well-electroporated and stage-matched spinal cords. The Hes5(e1ΔE) reporter exhibits a significant ventral shift in its activity and considerable overlap with Olig2 expression (blue dotted box). Box plots include the median and whiskers represent 5th and 95th percentiles. Data points that lay outside the DV scale used to assess these experiments were excluded from this analysis. ** $p = 0.0005$, Mann-Whitney test; $p = 0.6649$. Underlying data are provided in [S1 Data](#). (G) EGFP expression in Hes5(e1)-nEGFP whole mount embryos at e10.5. (H–H'') Cryosections of Hes5(e1)-nEGFP embryos at e10.5 assayed for GFP, Olig2, and Hes5. EGFP expression colocalizes with Hes5 expression (H'') but not with Olig2 (H). (I–N) Hes5(e1)-nEGFP expression in *Olig2* heterozygous (I, K, L) and homozygous mutants (J, M, N). In *Olig2* heterozygotes, little nEGFP expression can be detected in the Olig2 expression domain, resulting in a pronounced gap between the expression domains of EGFP, Nkx2.2, and Hes1 (K, L). By contrast, the EGFP, Nkx2.2, and Hes1 expression domains directly abut each other in *Olig2* homozygous mutants (M, N). β-Gal, beta-galactosidase; βGlob, beta-globin; CMV/β-actin::nLacZ, cytomegalovirus/chick beta-actin promoter driving nuclear LacZ gene expression; ΔE, E-box deletion; E-box, bHLH protein binding site; EGFP, enhanced green fluorescent protein; FP, floor plate; GFP, green fluorescent protein; H5(e1), Hes5(e1) genomic element; ns, not significant; pMN, motor neuron progenitor; WT, wild-type.

<https://doi.org/10.1371/journal.pbio.2003127.g008>

Hes5(e1)-βG::nEGFP activity was spatially restricted, with high levels of expression in the intermediate portions of the neural tube but little, if any, expression in both ventral and dorsal regions (Fig 8B and 8F). Strikingly, the ventral limit of Hes5(E1)-βG::nEGFP expression coincided with the dorsal border of the Olig2 expression domain (Fig 8B and 8F).

To determine whether the E-box within Hes5(e1) was essential for this spatially restricted expression pattern, we compared the activity of a Hes5(e1)-βG::nEGFP reporter construct in which the E-box had been mutated (Hes5(e1ΔE)-βG::nEGFP) (Fig 8D–8F). Loss of the E-box substantially reduced the overall activity of the nEGFP reporter, compared to the original construct (S8B and S8C Fig). In addition, nEGFP expression now showed abundant overlap with Olig2 in the ventral spinal cord (Fig 8E and 8F). Together, these results indicate that the Hes5(e1) element integrates both positive and negative regulatory information through its E-box.

Finally, to test whether Olig2 is responsible for the restriction of Hes5(e1)-βG::nEGFP from the pMN domain, we generated transgenic mice containing this construct that displayed activity throughout the neuraxis (Fig 8G). In agreement with the chick electroporation data, Hes5(e1)-βG::nEGFP activity was spatially restricted, with high levels of expression seen only in intermediate regions of the spinal cord, where high levels of Hes5 were expressed (Fig 8H–8J). The ventral extent of Hes5(e1)-βG::nEGFP activity coincided with the dorsal border of the pMN domain with little overlap between Olig2 and GFP (Fig 8H). By contrast, in *Olig2* mutant embryos, the expression of Hes5(e1)-βG::nEGFP extended ventrally to reach the dorsal boundary of Nkx2.2, a result that was not seen in control embryos (Fig 8K–8P). Together, these data provide evidence that Olig2 represses expression of Hes5 in the pMN domain, at least in part through direct interactions with the E-box site within Hes5(e1).

Discussion

Here, we provide a detailed molecular description of somatic MN differentiation. Single cell transcriptomics defines distinct phases of differentiation and reveals the regulatory relationships that drive progression from NPs to postmitotic MNs. Experimental validation confirmed these predictions and demonstrated that Olig2 plays a pivotal role coordinating growth and patterning by integrating differentiation and fate determination signals (Fig 9).

The trajectory of NP to MN differentiation

Single cell mRNA sequencing is emerging as a powerful tool to reconstruct transcriptional changes in cells during tissue development [33–36]. Here, we use pseudo-temporal ordering of




Fig 9. Olig2 coordinates patterning and neuronal differentiation. (A) Proposed model of the Olig2-controlled gene regulatory network. Olig2 not only acts as central organizer for dorsal-ventral patterning in the spinal cord but also controls the rate of MN differentiation through direct repression of Hes TFs. This leads to a higher levels of Ngn2 expression and, consequently, a higher rate of neuronal differentiation in the pMN domain, compared to adjacent progenitor domains. (B) Olig2 is a core component of the Shh-controlled gene regulatory network that patterns the ventral spinal cord [6,67]. (C) Olig2-mediated down-regulation of the Notch effectors Hes1/5 relieves repression of Ngn2 in the pMN domain. (D) Consolidated activities of Ngn2 and Olig2 cause differentiation of NPs to MNs. Olig2 promotes differentiation of MNs through repression of alternative IN cell fates. bHLH, basic helix-loop-helix; IN, interneuron; MN, motor neuron; NP, neural progenitor; pMN, MN progenitor; p2, V2 interneuron progenitor; p3, V3 interneuron progenitor; RA, retinoic acid; Shh, sonic hedgehog; TF, transcription factor; V2, V2 interneuron; V3, V3 interneuron.

<https://doi.org/10.1371/journal.pbio.2003127.g009>

cells based on their expression profile to obtain a high-resolution map of the developmental trajectory of MN differentiation (Fig 2). Examining gene expression along this timeline highlighted the dynamics of signalling pathways and transcriptional networks as cells transit from proliferative progenitors to postmitotic neurons. This computationally reconstructed trajectory accurately recapitulated the known changes in gene expression associated with MN generation in vivo and identified features of the dynamics not previously evident. This provides evidence that, by exploiting the inherent heterogeneity and asynchrony of differentiating cells that confound population-based assays, scRNA-seq allows the inference of transcriptional dynamics during developmental cell state transitions with high resolution. Moreover, the data illustrate how scRNA-seq analysis of a defined developmental process in vitro accurately predicts gene regulatory interactions and transcriptional dynamics in vivo.

Examination of the timeline revealed periods of relatively stable gene expression. Punctuating these were transition phases with marked differences in gene expression profiles, which coincided with changes in the signalling status within the cells. This is consistent with the saltatory view of cell fate specification, in which differentiation proceeds through a series of metastable states separated by coordinated signal-driven changes in gene expression [48]. Based on this observation, we used the global rate of change in gene expression in the pseudo-temporal orderings to develop a principled approach that objectively defines these phases. These distinct phases identified in MN differentiation corresponded to known cell types. Expression of *Irx3* marked early, uncommitted NPs, normally located in the intermediate spinal cord. These progenitors transition to pMN cells in response to Shh and retinoid signaling, and this was identifiable by the up-regulation of *Olig2* and down-regulation of *Irx3*. In addition, distinct phases in the acquisition of postmitotic MN identity could be identified with cells expressing markers such as *Lhx3*, *Isl1/2*, and *Chat* correctly positioned in the pseudo-temporal ordering.

The temporal ordering provided much greater resolution of the sequence of events leading to MN commitment than previously available. In particular, the transition from MN progenitor to MN was associated with a series of distinct and transient expression changes. This included the induction of well-known proneurogenic factors such as *Ngn2*, *Neurod1*, *Neurod4*, and *Hes6* (Fig 2E and S3F Fig). Increased expression of *Olig2* was also associated with this stage (Fig 2F). Consequently, the level of *Olig2* expression distinguished two sequential stages in MN progenitors during their differentiation. In the earlier phase, initiated as *Irx3* is down-regulated, pMN cells express low or moderate levels of *Olig2*. This is followed by the second phase, in which the levels of *Olig2* substantially increase and *Ngn2* becomes expressed at high levels (Fig 2C). In vivo analysis, together with the short-term lineage tracing afforded by the *Olig2*-mKate2 reporter, confirmed that *Olig2* up-regulation coincided with the commitment to differentiate into postmitotic MNs. By contrast, in the earlier phase of pMN development, the lower levels of *Olig2* appeared compatible with the transition of cells to *Nkx2.2* and *Fabp7* expressing p3 progenitors (S3C and S3D Fig). Together, these data provide new insight into the process of MN specification, identifying a series of distinct phases in NP differentiation to fate commitment and highlighting the changes in gene expression that characterise phase transitions.

Olig2 as a coordinator of neurogenesis

Previous studies have shown that both *Olig2* and *Ngn2* are required for the elaboration of MN identity and that *Olig2* activity induces *Ngn2* expression [13,17,18,21]. Consistent with these observations, progenitors in the *Olig2* expression domain differentiate at a much higher rate than cells in other progenitor domains of the neural tube [11,13]. Our results suggest a mechanism for this enhanced rate of neuronal differentiation. The canonical Notch effectors *Hes1* and *Hes5* act to suppress neurogenesis by inhibiting the expression of neurogenic bHLH

proteins, thus maintaining NPs in an undifferentiated state [24,25]. Olig2 activity represses *Hes1* and *Hes5*, thereby allowing expression of the proneural gene *Ngn2* and downstream effectors such as *Neurod4* (Fig 6 and S7 Fig). The ability of Olig2 to repress *Hes5* appears to be direct, as Olig2 binds to a conserved regulatory element within the *Hes5* locus that restricts gene expression from MN progenitors (Fig 7 and Fig 8). Similarly, Olig2 binding sites are found in putative regulatory elements associated with the *Hes1* gene, raising the possibility that this regulatory interaction is also direct. Consistent with a role for Olig2 in promoting neuronal differentiation, the levels of Olig2 transcript and protein peak at the onset of neurogenesis, concomitant with the induction of *Ngn2* in vivo and in vitro (Fig 2 and Fig 3). These findings therefore establish a mechanism by which neural patterning and neurogenesis intersect. In this view, by modulating the Notch pathway, the Shh and retinoid-dependent induction of Olig2 not only specifies MN identity but also determines the rate at which these progenitors differentiate, thus imposing the distinctive kinetics of MN production (Fig 9).

This model is surprising, as previous studies suggested antagonistic activities for Olig2 and *Ngn2* during the induction of neuronal target genes [28]. Both Olig2 and *Ngn2* have been shown to heterodimerize with E47 and bind to E-box elements, but with opposing activities [28,68]. In addition, similar to Id proteins, Olig2 proteins could potentially sequester E proteins (E12 and E47) from forming heterodimeric *Ngn2*/E-protein complexes that activate transcription [28,69]. The sequential expression of Olig2 and *Ngn2* has been proposed as a potential mechanism to reconcile the inhibitory activity of Olig2 on neurogenesis with the high rate of neurogenesis in the pMN domain [28]. However, our results suggest that this mechanism is unlikely to apply to the differentiation of MNs in the spinal cord for several reasons. The higher temporal resolution provided by the pseudo-temporal ordering indicated that primary *Ngn2* target genes such as *Dll1* and *Neurod4* are induced when the rate of Olig2 expression is maximal in cells (Fig 2E and S3F Fig). Furthermore, Olig2 protein perdures longer in differentiating MNs than *Ngn2*, resulting in significant coexpression of Olig2 and early MN markers such as *Lhx3* and *Mnx1* in *Ngn2*-negative cells (Fig 3H and S5B and S5C Fig). Hence, instead of sequential expression of these proteins, these results suggest that *Ngn2* is capable of mediating neurogenesis despite the presence of high Olig2 levels.

A potential solution to this puzzle may be that the activities of both Olig2 and *Ngn2* are regulated by phosphorylation. Olig2 phosphorylation at specific Ser/Thr residues regulates its choice of dimerization partner, intracellular localization, and DNA binding preference for open and closed chromatin [70–73]. Indeed, homodimeric complexes of Olig2 appear to mediate *Hes5* repression (Fig 7C and 7D). Furthermore, the cyclin-dependent kinases CDK1/2 have been proposed to phosphorylate Olig2 at Ser14, priming Olig2 for further phosphorylation at multiple Ser residues [74]. This phosphorylation appears to regulate the preference of Olig2 for open or closed chromatin and, thus, strongly influences its biological activity [71]. The declining levels of CDK1/2 during neurogenesis may similarly affect Olig2 activity to overcome its inhibitory role on neuronal gene expression. Similarly, phosphorylation of *Ngn2* affects its stability and interaction with Lim-homeodomain TF complexes and E-proteins [75–78]. Thus, additional posttranslational events extend the regulatory interactions between both proteins beyond stoichiometric interactions through protein–protein binding and competition for DNA binding sites. Notably, some of the relevant phosphorylations are performed by protein kinase A (PKA) and glycogen-synthase kinase 3 (GSK3), kinases linked to the activity of the Shh pathway, which appears to peak at the initiation of MN differentiation [6,11,72,75]. Connecting the activity of these neurogenic TFs to the activity of the Shh pathway would allow a tight coupling between MN generation and overall developmental dynamics dictated by the dynamics of morphogen signalling.

The pseudo-temporal ordering indicated that although *Olig2* levels peaked at the onset of MN differentiation, expression then decreased rapidly, prior to MNs reaching the next

metastable state along the differentiation trajectory, which is characterized by the induction of mature MN markers such as *Isl2* and *Chat* (Fig 2). This suggests that *Olig2* may need to be down-regulated to allow progression of MN differentiation. Consistent with this, overexpression of *Olig2* has been shown to inhibit the generation of MNs and to directly repress genes associated with MN identity, such as *Mnx1* [28,68]. Furthermore, the addition of *Olig2* to canonical reprogramming factors decreases the efficiency of conversion from fibroblasts to spinal MNs [31]. Thus, *Olig2* up-regulation can promote MN generation by initiating differentiation, but its down-regulation is needed to complete the switch from progenitor to postmitotic neuron. These dynamics of *Olig2* expression may help impose directionality to differentiation and ensure that the correct temporal sequence of gene expression occurs as MNs mature.

Oscillation of bHLH TFs in the spinal cord

The maintenance of NPs in the brain has been ascribed to the oscillatory expression of *Hes* and proneural bHLH TFs [65,79]. The *Hes* proteins are proposed to generate the oscillations by negatively regulating their own expression as well as *Ngn2* and *Ascl1* [25,80,81]. This phenomenon results in *Hes1* and proneural bHLH TFs exhibiting reciprocal expression phases at an equivalent frequency [65,79]. Oscillations in the levels of the Notch ligand *Dll1* have been reported in spinal cord progenitors [82]. In cortical progenitors, fluctuations in *Olig2* levels have also been documented, but these oscillations occur at a significantly slower frequency [65] and may therefore be regulated by a different mechanism.

Although we did not specifically investigate the occurrence of bHLH oscillations in the spinal cord in vitro or in vivo, our results may shed light on this question. The *Hes5(e1)* element can be bound by both *Olig2*-*Olig2* repression dimers and *Ngn2*-*E12* activation complexes (Fig 7B and 7C and S8A Fig). It is notable that mutation of the E-box in this element reduced the overall level of reporter activity in the spinal cord (S8B and S8C Fig) at the same time as it disrupted its spatial restriction from the pMN (Fig 8). These data are consistent with a model in which positive activators, such as *Ngn2* or other E-box binding factors, could interact with *Hes5(e1)* to directly elevate *Hes5* expression, which would in turn serve to repress *Ngn2* expression, thereby contributing to alternating phases of *Hes5* and *Ngn2* expression. In this regard, *Olig2* binding and repressing *Hes5* through this element would interrupt the oscillator, allowing *Ngn2* expression to reach its maximal levels and neuronal differentiation to commence. Thus, by inserting itself into the Notch-regulated neural differentiation program, *Olig2* shuts down Notch activity, ensuring MN development proceeds in a spatially and temporally controlled manner. This reconciles stochastic and oscillatory models of neuronal differentiation with the spatially predetermined pattern of neuron production observed in the spinal cord.

To examine *Olig2* expression, we used the relatively long half-life fluorescent protein mKate2, introduced into the *Olig2* genomic locus. Quantification of the levels of mKate2 and *Olig2* revealed a striking correlation between both proteins in NPs (S6D–S6F Fig). This argues against *Olig2* oscillations in these cells, as oscillatory behavior would be expected to decrease the correlation between both proteins. Although further investigation is necessary, the data are consistent with out-of-phase oscillations between *Ngn2* and *Hes5*, while *Olig2* levels steadily increase in MN progenitors over time. Understanding these relationships will provide insight into the transition from MN progenitor to differentiation.

The Notch pathway regulates *Olig2* expression and *Shh* signaling

Besides promoting neurogenesis, inhibition of Notch effectors also appears to be important for dorsal-ventral patterning of the neural tube and the consolidation of pMN identity. Patterning

of the ventral neural tube is mediated by a gene regulatory network that interprets both levels and duration of Shh signalling [6,42,67,83]. Previous studies have suggested that Notch signalling influences patterning of the ventral spinal cord by promoting the activity of the Shh pathway [61,84]. Consistent with this, overexpression of *HAIRY2*, the chick homologue of murine *Hes1*, causes a down-regulation of *Olig2* and induction of *Nkx2.2* in the pMN domain [84]. Similarly, sustained activation or inhibition of the Notch pathway causes, respectively, a ventral expansion or recession in p3 progenitors, located ventral to the pMN [61]. Here, we show that besides modulating Shh activity, Notch signalling can also regulate expression levels of *Olig2*. Conversely, *Olig2* represses the canonical Notch effector *Hes5* and could thereby negatively regulate the levels of Shh signalling in the pMN domain. Thus, *Olig2* may consolidate pMN identity not only by direct repression of other progenitor markers but also indirectly, by modulating levels of Shh signalling through its effect on Notch pathway.

Taken together, our data reveal a tight coupling between the gene regulatory networks that control patterning and differentiation in the ventral spinal cord. This highlights the pivotal role of *Olig2* in this process, which not only acts as central organizer of dorsal-ventral patterning in the spinal cord but also as developmental pacemaker for MN formation. The *Olig2*-mediated repression of Notch pathway targets provides a molecular mechanism for the much higher rate of neurogenesis observed in the pMN domain, compared to the rest of the spinal cord, and thereby explains the spatial and temporal patterns of neurogenesis observed in the neural tube. These findings raise the question of whether similar mechanisms also apply in other progenitor domains in the neural tube.

Materials and methods

Animal welfare

Animal experiments in the Briscoe lab were performed under UK Home Office project licenses (PPL80/2528 and PD415DD17) within the conditions of the Animal (Scientific Procedures) Act 1986. Animals were only handled by personal license holders. *Olig2^{Cre}* and *Ngn2^{K1GFP}* knock-in/knock-out mice were used as previously described [56,64] and interbred to create *Olig2* or *Ngn2* mutant embryos. All mice in the Novitsch lab were maintained and tissue collected in accordance with guidelines set forth by the UCLA Institutional Animal Care and Use Committee. Fertilized chicken eggs were acquired from AA McIntyre Poultry and Fertile Eggs, incubated, and electroporated as previously described [85].

Differentiation of NPs from mouse ESCs

NPs were differentiated as described previously [37]. In brief, HM1 (Thermo Scientific), DVI2, and *Olig2::T2A-mKate2* ESCs were maintained in ES cell medium with 1,000 U/ml LIF on mitotically inactivated mouse embryonic fibroblasts (feeder cells). DVI2 cells were generated by integrating an 8xGBS-H2B::Venus Shh pathway reporter into the HPRT locus of HM1 cells and used for all ESC experiments except 4-color stainings in S5A and S5B Fig, which rely on HM1 cells, and experiments in Fig 4 and S6 Fig, which were conducted using the *Olig2::T2A-mKate2* reporter cell line.

For differentiation, cells were dissociated in 0.05% Trypsin (Gibco) and replated onto tissue culture plates for 25 minutes to remove feeder cells. Cells staying in the supernatant were spun down and resuspended in N2B27 medium at a concentration of 10^6 cells/ml. Forty-five thousand cells were plated onto 35-mm CellBind dishes (Corning) precoated with 0.1% Gelatine solution in 1.5 ml N2B27 + 10 ng/ml bFGF. At D2, the medium was replaced with N2B27 + 10 ng/ml bFGF + 5 μ M CHIR99021 (Axon). At D3 and every 24 hours afterwards, the medium was replaced with N2B27 + 100 nM RA (Sigma) + 500 nM SAG (Calbiochem). For Notch

inhibition, differentiations were treated at day 5 with N2B27 + 100 nM RA + 500 nM SAG + 10 ng/μl DBZ (Tocris Biosciences) for 24 hours. Cells were washed with N2B27 medium at later medium changes, when many dead cells were detected in the dish.

qPCR analysis

mRNA was extracted using RNeasy Mini Kit (Qiagen) according to the manufacturer's instructions. 1.5–2 μg of RNA was used for reverse transcription using Super-Script III First-Strand Synthesis kit (Invitrogen) with random hexamers. Platinum SYBR Green qPCR mix (Invitrogen) was used for amplification on a 7900HT Fast Real Time PCR machine (Applied Biosystems). Expression values were normalized against β-actin. Three independent repeats of each RT-qPCR time course were performed and three independent samples at each time point of each repeat were analyzed. For a complete list of used primers, see [S3 Table](#). qPCR data presented in [Fig 1](#), [S1 Fig](#), and [S6 Fig](#) show one representative repeat and show mean ± standard deviation. The heat map in [S2B Fig](#) was plotted using Graphpad Prism 7.

Immunofluorescent stainings

Cells were washed using N2B27 medium and PBS (Gibco) and then fixed in 4% paraformaldehyde in PBS at 4°C for 20 minutes. After fixation, cells were washed twice with PBS and stored in a refrigerator until stainings were performed. For staining, cells were washed three times in PBS containing 0.1% Triton X-100 (PBS-T). Primary and secondary antibodies were diluted in PBS-T + 1% BSA. Cells were incubated with primary antibodies overnight at 4°C, then washed three times for 5–10 minutes in PBS-T, incubated with secondary antibodies for 1 hour at room temperature, and washed again three times in PBS-T. Stainings were mounted using ProLong Gold Antifade reagent (Life Technologies). Mouse and chicken spinal cord tissues were fixed with 4% paraformaldehyde, cryoprotected in 30% sucrose, sectioned, and processed for immunohistochemistry or in situ hybridization, as previously described [[85,86](#)].

Antibodies against a peptide in the C-terminal portion of mouse Hes5 (APAKEPPAPGA APQPARSSAK, aa 127–147) were raised in rabbits and guinea pigs (Covance). The rabbit serum was affinity purified and used at 1:8,000 and the crude guinea pig serum at 1:16,000. Additional primary antibodies were used as follows: goat anti-β-galactosidase (Biogenesis 4600–1409 1:2,000), mouse anti-Cre (Covance MMS-106P, 1:2,000), rabbit anti-Dbx1 (kind gift of Susan Morten and Thomas Jessell, 1:8,000), rabbit anti-Fabp7 (Abcam ab32423, 1:2,000 or Chemical AB9558, 1:2,000), rat anti-FLAG (Stratagene 200474, 1:1,500), chicken anti-GFP (Abcam ab13970, 1:20,000), sheep anti-GFP (AbD Serotec 4745–1051, 1:800), rabbit anti-Hes1 ([[87](#)], 1:1,000), mouse anti-Hoxc6 (Santa Cruz Biotechnology sc-376330, 1:250), mouse anti-Hb9/Mnx1 (DSHB, 1:40), mouse anti-Isl1/2 (DSHB, 1:100), goat anti-Isl1 (R&D AF1837, 1:1,000), rabbit anti-Lhx3 (Abcam ab14555, 1:500), mouse anti-NeuN (Rbfox3, Chemicon/Millipore MAB377, 1:1,000), rat anti-chick Neurod4 (NeuroM [[88](#)]), goat anti-Ngn2 (Santa Cruz Biotechnology sc-19233, 1:500), mouse anti-Ngn2 (5C6, [[89](#)], 1:50), guinea pig anti-chick Ngn2 ([[16](#)], 1:32,000), mouse anti-Nkx2.2 (DSHB, 1:25), mouse anti-Nkx6.1 (DSHB, 1:100), rabbit anti-Olig2 (Millipore AB9610, 1:1,000), guinea pig anti-mouse Olig2 ([[90](#)] 1:20,000), guinea pig anti-chick Olig2 ([[13](#)], 1:8,000), rabbit anti-Pax6 (Millipore AB2237, 1:1,000), mouse anti-Pax6 (DSHB, 1:25), goat anti-Sox1 (R&D AF3369, 1:500), goat anti-Sox2 (Santa Cruz Biotechnology sc-17320, 1:2,000), rabbit anti-Sox2 ([[88](#)], 1:2500), rabbit anti-TagRFP (Evrogen AB233, 1:1,000), rabbit anti-Tubb3 (Covance PRB-435P, 1:2,000), mouse anti-Tubb3 (Covance MMS-435P, 1:1,000), rabbit anti-Zbtb18 (Proteintech 12714-1-AP, 1:1,000).

Secondary antibodies used throughout this study were raised in donkey. Alexa488, Alexa568, Cy3, and Dylight 647-conjugated antibodies (Life Technologies or Jackson

Immunoresearch) were diluted 1:1,000 and Alexa647 conjugated antibodies (Life Technologies) 1:500. Cy5-conjugated antibodies (Jackson Immunoresearch) were diluted 1:700 and CF405M donkey anti-guinea pig secondary antibody (Sigma) 1:250.

Image acquisition and analysis

Immunofluorescent images of ESC-derived NPs were acquired using a Zeiss Imager.Z2 microscope equipped with an Apotome.2 structured illumination module and a 20× magnification lens (NA = 0.75). Five phase images were acquired for structured illumination. For each image, z-stacks composed of 12 sections separated by 1 μm were acquired. Maximum intensity projection was performed in Fiji.

Cryosections were documented using a Leica SP5 confocal microscope equipped with a 40× oil objective, or Zeiss LSM5, LSM700, or LSM800 confocal microscopes and Zeiss Apotome imaging systems equipped with 10×, 20×, and 40× oil objectives. For nuclear staining intensity measurements, 3–4 individual sections separated by 1 μm were analyzed. Nuclei segmentation and intensity measurement were performed in CellProfiler. Data were normalized and plotted using R. Other images were processed and manually quantified using Fiji and Adobe Photoshop imaging software.

Single cell sequencing

NPs were dissociated using 0.05% Trypsin (Gibco) spun down in ES-medium, resuspended, washed, and spun down in 10 ml PBS (Gibco). Afterwards, cells were resuspended in 1 ml N2B27 and filtered into a FACS tube (Falcon). The Fluidigm C1 platform was used to capture individual cells using 96 small or medium IFC chips. Cells were diluted in the range of 250,000–400,000 cells per ml for chip loading. Capturing efficiency was evaluated by manually inspecting each capture site on the chip using the automated NanoEntek JuLi cell imager. Only capture sites containing single cells were processed for library preparation and sequencing. Single cell full-length cDNA was generated using the Clontech SMARTer Ultra Low RNA kit on the C1 chip using manufacturer-provided protocol. ArrayControl RNA Spikes (AM1780) were added to the cell lysis mix, as recommended in the Fluidigm protocol. Libraries were prepared using the Illumina Nextera XT DNA Sample Preparation kit, according to a protocol supplied by Fluidigm, and sequenced on Illumina HiSeq 2500 or 4000 using 50- or 75-bp paired-end runs.

Generation of Olig2::T2A-mKate2 ESC line by CRISPR

pNTKV-T2A-3xNLS-FLAG-mKate2 was generated by cloning a T2A-3XNLS-FLAG-mKate2 cassette into pNTKV using HpaI and HindIII restriction sites. To integrate the T2A-3xNLS-FLAG-mKate2 cassette at the 3' end of the Olig2 open reading frame, a donor vector comprising app. 2.8 kb upstream and 5 kb downstream of the stop codon was constructed. For CRISPR/Cas9-mediated homologous recombination, a short guide RNA (sgRNA) sequence (CGGCCAGCGGGGTGCGTCC) was cloned into pX459 (Addgene), according to [91].

For electroporation, DVI2 ESCs were grown in 2i medium + LIF. 4 μg of both plasmids were electroporated into 4×10^6 cells using Nucleofector II (Amaxa) and mouse ESC Nucleofector kit (Lonza). Afterwards, cells were replated onto 10-cm CellBind plates (Corning) and maintained in 2i medium + LIF. For selection, cells were first treated with 1.5 μg/ml Puromycin (Sigma) for two days and afterwards with 50 μg/ml Geneticin (Gibco) until colonies were clearly visible. Individual colonies were picked using a 2-μl pipette, dissociated in 0.25% Trypsin (Gibco), and replated onto feeder cells in ES-medium + 1,000 U/ml LIF in a 96-well plate. Correct integration of the T2A-3xNLS-FLAG-mKate2 transgene was verified using long-range PCRs.

Western blots

Cells were lysed in RIPA buffer supplemented with protease inhibitors. 10 µg of total protein was loaded per lane. Antibodies used were rabbit anti-Olig2 (Millipore AB9610, 1:3,000) and mouse anti-β-tubulin (Sigma T4026, 1:2,000). Secondary antibodies were donkey anti-mouse IRDye 800CW and donkey anti-rabbit IRDye 680RD (both Licor). Blots were scanned using an Odyssey Scanner (Licor).

Flow cytometry

To quantify the number of Olig2::T2A-mKate2 positive cells, NPs were trypsinized in 0.05% Trypsin (Gibco) and spun down in ES medium. Cells were resuspended in PBS (Gibco) supplemented with the live-cell staining dye Calcein Violet (Life Technologies), according to the manufacturer's instructions. Flow analysis was performed using a Becton Dickinson LSRII flow cytometer. HM1 or DVI2 cells were differentiated in parallel and analyzed using the same settings to estimate the number of mKate2 positive cells in Fig 4L and S6H Fig. The threshold for counting cells as mKate2 positive was set to the intensity for which 0.5% of cells without the mKate2 transgene were counted as positive. Thirty thousand events were recorded for each replicate. To count cells as mKate2^{HIGH} cells in Fig 4L and S6G Fig, a threshold was set to the shoulder visible in the histograms of the control conditions depicted in Fig 4L. This shoulder typically appears at day 6 and is not present in day 5 cells. Based on the flow cytometry data in S6C Fig and the correlation between mKate2 fluorescence and Isl1/2 expression shown in Fig 4H, we infer that most mKate2^{HIGH} cells are MNs. Cells were counted as mKate2^{HIGH} if their mKate2 intensity exceeded this threshold.

For analysis of Tubb3 stainings by flow cytometry (S6 Fig), cells were fixed for 20 minutes in 2% PFA on ice, washed three times in PBS-T, and incubated with Alexa647-conjugated anti-Tubb3 antibody (BD Pharmingen, 1:10) in PBS-T + 1% BSA for one hour at room temperature. Cells were afterwards washed 3× in PBS-T and endogenous mKate2 fluorescence, and Tubb3 staining in 10,000 cells was quantified by flow cytometry. Data were analyzed using FlowJo.

Electrophoretic mobility shift assays

pCS2+ plasmid expression vectors for *Olig2*, *E12*, *Ngn2*, and *Id1* [13] were transcribed and translated in vitro using the Promega TNT Coupled Wheat Germ Extract System. Programmed extracts were mixed as indicated in a buffer containing 100 mM Hepes pH 7.6, 25 mM KCl, 1.5 mM MgCl₂, 0.2 mM EDTA, 2.5% glycerol, and 100 ng poly dIdC and incubated for 15 minutes at room temperature. ³²P-dCTP-labeled probes were generated by Klenow end labeling of double-stranded oligonucleotides containing the native mouse Hes5(e1) sequence (forward 5'-ggccgCTCCCAAAGACCATCTGGCTCCGTGTTATAA-3'; reverse 5'-actagTTATAACACGGAGCCAGATGGTCTTTTGGGAG-3') or an E-box mutated version (forward 5'-ggccgCTCCCAAAGAggATCccGCTCCGTGTTATAA-3'; reverse 5'-actagTTATAACACGGAGCggGATccTCTTTTGGGAG-3'). The E-box sequence is underlined. Lowercase indicates substitutions and added flanking sequences. Samples were incubated with labeled probes for 15 minutes before resolving on a 4.5% polyacrylamide gel and subsequent autoradiography. Probe competition was achieved by incorporating unlabeled oligonucleotide probes in the binding reaction mix.

Hes5(e1) transgenic assays

Mouse and chick *Hes5(e1)* genomic DNA fragments were amplified by PCR using the following primers: mouse, forward 5'-gagcggcgcCGGTTCCACACTTTGGT-3'; reverse 5'-

gagactagtCACAGTCCCAAGCTGCTTAAA-3', and chick, forward 5'-gaggcgccgcTGC GTTT CCCATACTTTTCC-3'; reverse 5'-gagactagtTCTGGCCTTGAAGCTAGGAG-3'. Lowercase indicates added flanking sequences with restriction enzyme sites (NotI and SpeI) underlined. PCR products were digested and cloned into a reporter construct containing the β -globin basal promoter, a nuclear *EGFP* coding sequence, and a bovine growth hormone polyadenylation sequence (β G::nGFP [92]). Mutations of the *Hes5(e1)* E-box were generated through splicing by overlap extension PCR. Chick embryos were co-electroporated with chick *Hes5(e1)* constructs along with a plasmid vector, producing nuclear-tagged β -galactosidase under the control of the cytomegalovirus enhancer and β -actin promoter. Embryos were collected, fixed, and cryosectioned. Sections were stained using antibodies to β -galactosidase and Olig2 and fluorescent secondary antibodies. GFP levels were measured based on its native fluorescence. Images were collected and positions of cells expressing each marker rendered using the spots function of the Bitplane Imaris 8.4 imaging suite. Calculated positions were exported and processed using Microsoft Excel and Graphpad Prism 7 software.

Transgenic mice expressing the mouse *Hes5(e1)*- β G::nGFP reporter were generated with the assistance of the University of Michigan Transgenic Animal Model Core by microinjection of purified plasmid DNA into fertilized eggs obtained by mating (C57BL/6 X SJL)F1 female mice with (C57BL/6 X SJL)F1 male mice and subsequent transfer to pseudo-pregnant recipients. Analysis was conducted on both embryos collected from the primary reporter injections and offspring collected from matings of a transgenic line that passed through the germ line.

Electroporation and in situ hybridization

Chick embryos were electroporated at HH stages 11–13 with RCAS-myc-tagged chick *Olig2* and *Olig2*-bHLH-Engrailed plasmid constructs [13] and collected at HH stages 21–23. Spinal cord sections were hybridized with digoxigenin-UTP labeled RNA probes generated from plasmid DNA or templates generated by PCR. 3' UTR sequences for chick *HES5-1* and *HES5-3* were amplified from spinal cord cDNA with the following primers: *HES5-1*, forward 5'-GCG GAATTCAGGGAAGCTCTCACTTAGTGAAC-3' and reverse 5'-GCGCTCGAGATACCTT CCTGCTGAAGACATTTGC-3'; *HES5-3*, forward 5'-GCGGAATTCGCCAAGAGCACGC TCACCATCACCT-3' and reverse 5'-GCGCTCGAGCTACACAGCTTGAGTTATGGTTT AG-3' and directionally cloned into the pBluescript. Underlined sequences indicate restriction enzyme sites incorporated into the primers. Chick *HAIRY1* and *HES5-2* 3' UTR riboprobes were generated as previously described [85].

Chromatin immunoprecipitation-PCR

ESC-derived MN progenitors were dounce homogenized and sonicated in 3 ml lysis buffer (1% SDS, 50 mM Tris pH 8.0, 20 mM EDTA, 1 mM PMSF, and 1X Complete protease inhibitor cocktail [Roche]). 150 μ g of lysate DNA were used per immunoprecipitation reaction and mixed with 3–5 μ l of either rabbit anti-Olig2 antibodies (Millipore AB9610), rabbit anti-Ngn2 serum (generous gift of Dr. Soo-Kyung Lee, Oregon Health Sciences University), normal rabbit sera, or purified rabbit IgG. Antibody-chromatin complexes were collected using Dynabeads protein A (Invitrogen), washed and eluted DNA used for RT-qPCR in triplicate using the following primer pairs: *Hes5(e1)* forward 5'-CTGCTTCTGAATGAATGAGGGCGG-3' and reverse 5'-AGCAGACGAGCCCTTTATTGCTCT-3'; *Hes5(e2)*, a nonconserved element 3' to the *Hes5* coding exons that contains an E-box, forward 5'-AGATGGCTCAGCGGTAA GAG-3' and reverse 5'-CCATGTGGTTGCTGGGATTTG-3'. Fold enrichment for each region was calculated as compared to normal rabbit serum or purified IgG.

Supporting information

S1 Fig. Characterization of Hox gene expression in NPs and MNs. (A) Expression of the somatic MN marker *Mnx1* in MNs at day 6. (B) RT-qPCR analysis of *Hox* genes expression levels from day 3 to day 7. Underlying data are provided in [S1 Data](#). (C) *Hoxc6* expression in MNs characterized by *Isl1* and *Tubb3* expression from day 6 to day 8. Scale bars = 40 μ m. MN, motor neuron; NP, neural progenitor; RT-qPCR, real time-quantitative polymerase chain reaction; *Tubb3*, neuronal class III beta-tubulin.

S2 Fig. Establishment of different NP identities by different levels of Shh pathway activation. (A) Schematic of the embryonic spinal cord. Expression domains of TFs defining NP domains are indicated. (B) RT-qPCR analysis of day 6 differentiations treated with 0–1,000 nM SAG after day 3. (C) Expression of *Dbx1*, *Nkx6.1*, and *Isl1* in day 6 differentiations treated with the indicated concentrations of SAG. (D) Expression of *Pax6*, *Olig2*, and *Nkx2.2* in day 6 differentiations treated with the indicated concentrations of SAG. Scale bars = 40 μ m. NP, neural progenitor; Shh, sonic hedgehog; TF, transcription factor; RT-qPCR, real time-quantitative polymerase chain reaction; SAG, Smoothened/Shh signalling agonist.

S3 Fig. Identification of gene modules and cell states by hierarchical clustering of single cell sequencing data. (A) Identification of cell states by hierarchical clustering from 202 cells based on 10 identified gene modules. Genes characteristic for the individual modules are indicated. The boxed region corresponds to the heat map in [Fig 2A](#). (B) Quantifications of read counts per cell (top) and number of expressed genes per cell (bottom) for neural cell states identified by hierarchical clustering. Colors of the graphs match cell states in [Fig 2A](#) and [S3A Fig](#). (C) Cell state graphs color coded for the expression levels of *Olig2*, *Nkx2.2*, and *Fabp7*. (D) Analysis of *Olig2*, *Nkx2.2*, and *Fabp7* expression in differentiations at day 6 (top row) and e10.5 embryonic spinal cords (bottom row) confirms higher *Fabp7* expression levels in p3 progenitors. (E) The transition phase from early *Irx3* NPs to *Olig2* NPs correlates with the induction of Shh target genes *Ptch2*, *Gli1*, *Hhip*. (F) Inhibition of Notch signalling, revealed by decreasing expression levels of *Hes1/5* and expression of the Notch ligand *Dll1* and the pathway inhibitors *Hes6* and *Numbl*, identifies the cell state transition from NPs to MNs. Scale bars = 25 μ m (D, top row) and 50 μ m (D, bottom row). e, embryonic day; NP, neural progenitor; Shh, sonic hedgehog.

S4 Fig. Robustness analysis of gene expression dynamics by bootstrapping. Solid lines indicate original gene levels shown in [Figs 2E, 2F](#) and [S3E and S3F](#). At each pseudo-time point, box plots indicate median, first, and third quartiles of the gene level distribution obtained from 1,000 bootstrapped datasets. Whiskers indicate the largest and smallest values no further than 1.5 times the interquartile range, taken from the hinge. The associated correlation coefficient, r , is the average of the Spearman correlation coefficients over all pairs of bootstrap replicates.

S5 Fig. Validation of predictions from the pseudo-temporal ordering. (A) Sequential expression of *Olig2*, *Ngn2*, *Lhx3*, and *Isl1* during MN differentiation, revealed by immunofluorescent staining for these markers at day 6 of differentiation. (B,C) Quantification of levels of *Olig2*, *Isl1*, *Ngn2* (color code in B), and *Lhx3* (color code in C) reveals a clear differentiation path from *Olig2*^{HIGH} cells to MNs and sequential induction of *Ngn2* and *Lhx3* during this process ($n = 2,236$ nuclei). Underlying data are provided in [S1 Data](#). (D) Staining for *Isl1*, *Lhx3*,

and *Tubb3* reveals high levels of *Tubb3* expression in *Isl1*-positive but not *Lhx3*-positive MNs at day 6 of differentiation. This is consistent with the earlier MN stage of *Lhx3* MNs. (E, F) Most positive and negative Spearman-correlated transcription factors for *Olig2* (E) and *Ngn2* (F) reveal *Zbtb18* (green in E–G) as a novel gene involved in MN formation. Underlying data are provided in [S1 Data](#). (G–G'') Immunofluorescent staining for *Olig2* (G), *Zbtb18* (G'), and *Ngn2* (G'') at day 6 of differentiation. (H, I) Quantification of levels of *Olig2*, *Ngn2* (H), and *Zbtb18* (I) in individual nuclei reveals a good correlation between these markers ($n = 1,431$ nuclei). Underlying data are provided in [S1 Data](#). (J–L) Analysis of *Olig2*, *Ngn2*, and *Zbtb18* expression in neural tubes at e9.5 (J), e10.5 (K), and e11.5 (L). Note that *Ngn2* and *Zbtb18* are expressed in cells with high levels of *Olig2* at e9.5 and e10.5, but not at e11.5 (left insets in K–M). In addition, *Zbtb18* and *Ngn2* are coexpressed in nuclei at the edge of the progenitor domain in dorsal areas of the neural tube at e10.5 (L) and e11.5 (M) (right insets). Scale bars = 25 μm in (A,D), 10 μm in (G) and insets in J–L, 50 μm in J–L. e, embryonic day; MN, motor neuron; *Tubb3*, neuronal class III beta-tubulin. (TIF)

S6 Fig. Characterization of the *Olig2*-mKate2 reporter cell line by flow cytometry and upon Notch inhibition (A–C) Quantification of mKate2 and *Tubb3* fluorescence intensity by flow cytometry at day 4 to day 6 of differentiation. Note that high levels of *Tubb3* are predominantly detected in mKate2^{HIGH} cells at day 6 (C). (D–F) Correlation between *Olig2* and mKate2 levels in individual nuclei quantified from images in [Fig 4C–4F](#). Plots are color coded for levels of *Isl1/2* (D), *Sox1* (E), and *Nkx2.2* (F). (G) Quantification of the fold change in mKate2^{HIGH} cells (see [Fig 4L](#)) upon 24 hours Notch inhibition for five experimental repeats by flow cytometry. Each repeat consists of the measurement of three independent dishes for control and Notch inhibition from the same differentiation. Underlying data are provided in [S1 Data](#). *** $p < 0.001$, unpaired t test. (H) Fold change of mKate2-positive cells (see [Fig 4L](#)) upon Notch inhibition (grey) relative to untreated control differentiations (black). Notch inhibition does not cause an overall change in the number of mKate2 positive cells. Underlying data are provided in [S1 Data](#). * $p < 0.05$; ** $p < 0.01$, unpaired t test. (I) Quantification of mKate2 and *Tubb3* fluorescence intensity by flow cytometry upon 24 hours Notch inhibition. Note that most mKate2^{HIGH} cells differentiated into MNs (compare to [S6C Fig](#)). (J–L) RT-qPCR quantification of expression levels of progenitor markers *Sox1*, *Hes5*, *Hes1*, and *Pax6* (J); neurogenesis markers *Olig2*, *Ngn2*, *Zbtb18*, and *Pou3f2* (K); and MN markers *Tubb3* and *Isl1* (L) after 0, 12, and 24 hours of Notch inhibition (grey) and in untreated controls (black). Note that *Olig2* expression increases in contrast to other progenitor markers after 12 hours of Notch inhibition. Underlying data are provided in [S1 Data](#). MN, motor neuron; RT-qPCR, real time-quantitative polymerase chain reaction; *Tubb3*, neuronal class III beta-tubulin. (TIF)

S7 Fig. *Olig2*, not *Ngn2*, is required for the repression of *Hes5*, which is necessary for the formation of MNs. (A–D'') Staining of wild-type (A–B'') and *Ngn2*^{K1GFP} mutant (C–D'') embryonic spinal cords for *Olig2*, *Ngn2*, GFP, and *Hes5* at e9.5 (A,C) and e10.25 (B,D). (E–F'') GFP expression (E,F) is still increased and *Hes5* expression (E'',F'') is still reduced in the pMN domain in *Ngn2*^{K1GFP} mutant spinal cords (same sections as C–D''). The yellow dotted line indicates the dorsal boundary of the pMN domain. (G–J) Ectopic expression of cHES5-2 does not affect levels of the progenitor markers *SOX2* (G), *NKX6.1* (H), *PAX6* (I), and *OLIG2* (J). (K–P) Ectopic expression of cHES5-2 (N–P) leads to a reduction of *NGN2* (K,N), *NEUROD4* (L,O), and *NEUN* (M,P). (K–M) These show control electroporations with a nuclear EGFP (nEGFP) expression construct. (Q) Quantification of the effect of ectopic cHES5-2 expression on expression levels of *NGN2*, *NEUROD4*, and *NEUN* relative to nEGFP controls. Underlying

data are provided in [S1 Data](#). **** $p < 0.0001$; *** $p < 0.0005$, Mann-Whitney test; Scale bars = 20 μm (A–A'', C–C'', G–P), 50 μm (B–B'', D–D''). cHES5-2, chick HES5-2 gene; e, embryonic day; EGFP, enhanced green fluorescent protein; GFP, green fluorescent protein; MN, motor neuron; nEGFP, nuclear EGFP; pMN, MN progenitor. (TIF)

S8 Fig. Olig2 and Ngn2 bind to Hes5(e1) in vivo. (A) Both Olig2 and Ngn2 antibodies precipitate the *Hes5(e1)* genomic element from ESC-derived MN progenitors, but not *Hes5(e2)*, an unrelated genomic element 3' to the *Hes5* coding exons that also contains an E-box. Fold enrichment relative to normal rabbit sera or purified IgG is displayed. **** $p < 0.0001$; ** $p < 0.01$, Mann-Whitney test. Underlying data may be found in [S1 Data](#). (B,C) Comparison between Hes5(e1)- $\beta\text{G}::n\text{EGFP}$ (top row) and Hes5(e1 ΔE)- $\beta\text{G}::n\text{EGFP}$ (bottom row) reporter activities. Sections were imaged using identical settings for each pair. The overall activity of the Hes5(e1 ΔE)- $\beta\text{G}::n\text{EGFP}$ reporter is lower than that of the Hes5(e1)- $\beta\text{G}::n\text{EGFP}$ reporter. Scale bars = 50 μm . E-box, bHLH protein binding site; ESC, embryonic stem cell. (TIF)

S1 Table. Gene modules describing the biological processes represented in the scRNA-seq dataset. scRNA-seq, single cell RNA sequencing. (CSV)

S2 Table. GO annotations of the 22 gene modules ($p < 0.05$). GO, gene ontology. (CSV)

S3 Table. List of qPCR primers. qPCR, quantitative polymerase chain reaction. (XLSX)

S1 Text. Analytical supplement. (DOCX)

S1 Data. (XLSX)

Acknowledgments

We are grateful to Leena Bhaw and Abdul Sesay for excellent support with single cell sequencing, Supraja Varadarajan for assistance with Imaris image processing, and Vicki Metzis for help with processing and visualizing ChIP-Seq data. We thank David Anderson, Thomas Edlund, Thomas Jessell, Soo-Kyung Lee, Susan Morton, and Tetsuo Sudo for reagents; Debora Keller and Mina Gouti for providing the DVI2 mouse ESC line; Francois Guillemot for kindly providing *Ngn2*^{K1GFP} mice; and Lorena Belen Garcia Perez, Teresa Rayon Alonso, and Christopher Demers for comments on the manuscript. The Hes5 antisera were generated in Thomas Jessell's laboratory with support from the Howard Hughes Medical Institute and NINDS.

Author Contributions

Conceptualization: Andreas Sagner, Zachary B. Gaber, Julien Delile, Jennifer H. Kong, James Briscoe, Bennett G. Novitch.

Funding acquisition: James Briscoe, Bennett G. Novitch.

Investigation: Andreas Sagner, Zachary B. Gaber, Julien Delile, Jennifer H. Kong, David L. Rouso, Caroline A. Pearson, Steven E. Weicksel, Manuela Melchionda, S. Neda Mousavy Gharavy, James Briscoe, Bennett G. Novitch.

Methodology: Andreas Sagner, Zachary B. Gaber, Julien Delile, Jennifer H. Kong, David L. Rouso, Caroline A. Pearson, Steven E. Weicksel, S. Neda Mousavy Gharavy, Bennett G. Novitch.

Project administration: James Briscoe, Bennett G. Novitch.

Software: Julien Delile.

Supervision: James Briscoe, Bennett G. Novitch.

Validation: Bennett G. Novitch.

Visualization: Andreas Sagner, Zachary B. Gaber, Julien Delile, Jennifer H. Kong, David L. Rouso, Caroline A. Pearson, Steven E. Weicksel, S. Neda Mousavy Gharavy, Bennett G. Novitch.

Writing – original draft: Andreas Sagner, Zachary B. Gaber, Julien Delile, James Briscoe, Bennett G. Novitch.

Writing – review & editing: Andreas Sagner, Julien Delile, Manuela Melchionda, James Briscoe, Bennett G. Novitch.

References

- Davidson EH. Emerging properties of animal gene regulatory networks. *Nature*. Nature Publishing Group; 2010; 468: 911–920. <https://doi.org/10.1038/nature09645> PMID: 21164479
- Stathopoulos A, Levine M. Genomic regulatory networks and animal development. *Dev Cell*. 2005; 9: 449–462. <https://doi.org/10.1016/j.devcel.2005.09.005> PMID: 16198288
- Briscoe J, Pierani A, Jessell TM, Ericson J. A homeodomain protein code specifies progenitor cell identity and neuronal fate in the ventral neural tube. *Cell*. 2000; 101: 435–445. PMID: 10830170
- Ribes V, Briscoe J. Establishing and interpreting graded Sonic Hedgehog signaling during vertebrate neural tube patterning: the role of negative feedback. *Cold Spring Harb Perspect Biol*. 2009; 1: a002014. <https://doi.org/10.1101/cshperspect.a002014> PMID: 20066087
- Briscoe J, Ericson J. The specification of neuronal identity by graded Sonic Hedgehog signalling. *Semin Cell Dev Biol*. 1999; 10: 353–362. <https://doi.org/10.1006/scdb.1999.0295> PMID: 10441550
- Balaskas N, Ribeiro A, Panovska J, Dessaud E, Sasai N, Page KM, et al. Gene regulatory logic for reading the Sonic Hedgehog signaling gradient in the vertebrate neural tube. *Cell*. 2012; 148: 273–284. <https://doi.org/10.1016/j.cell.2011.10.047> PMID: 22265416
- Cohen M, Briscoe J, Blassberg R. Morphogen interpretation: the transcriptional logic of neural tube patterning. *Curr Opin Genet Dev*. 2013; 23: 423–428. <https://doi.org/10.1016/j.cde.2013.04.003> PMID: 23725799
- Jessell TM. Neuronal specification in the spinal cord: inductive signals and transcriptional codes. *Nat Rev Genet*. 2000; 1: 20–29. <https://doi.org/10.1038/35049541> PMID: 11262869
- Lee SK, Pfaff SL. Transcriptional networks regulating neuronal identity in the developing spinal cord. *Nat Neurosci*. 2001; 4 Suppl: 1183–1191. <https://doi.org/10.1038/nn750> PMID: 11687828
- Alaynick WA, Jessell TM, Pfaff SL. SnapShot: Spinal cord development. *Cell*. Elsevier; 2011; 146: 178.e1. <https://doi.org/10.1016/j.cell.2011.06.038> PMID: 21729788
- Kicheva A, Bollenbach T, Ribeiro A, Valle HP, Lovell-Badge R, Episkopou V, et al. Coordination of progenitor specification and growth in mouse and chick spinal cord. *Science*. American Association for the Advancement of Science; 2014; 345: 1254927. <https://doi.org/10.1126/science.1254927> PMID: 25258086
- Ericson J, Thor S, Edlund T, Jessell TM, Yamada T. Early stages of motor neuron differentiation revealed by expression of homeobox gene *Islet-1*. *Science* (80-). 1992; 256: 1555–1560.
- Novitch BG, Chen AI, Jessell TM. Coordinate regulation of motor neuron subtype identity and pan-neuronal properties by the bHLH repressor *Olig2*. *Neuron*. 2001; 31: 773–789. [https://doi.org/10.1016/S0896-6273\(01\)00407-X](https://doi.org/10.1016/S0896-6273(01)00407-X) PMID: 11567616
- Zhou Q, Anderson DJ. The bHLH transcription factors *OLIG2* and *OLIG1* couple neuronal and glial subtype specification. *Cell*. 2002; 109: 61–73. PMID: 11955447

15. Lu QR, Sun T, Zhu Z, Ma N, Garcia M, Stiles CD, et al. Common Developmental Requirement for Olig Function Indicates a Motor Neuron/Oligodendrocyte Connection. *Cell*. 2002; 109: 75–86. [https://doi.org/10.1016/S0092-8674\(02\)00678-5](https://doi.org/10.1016/S0092-8674(02)00678-5) PMID: 11955448
16. Skaggs K, Martin DM, Novitsch BG. Regulation of spinal interneuron development by the Olig-related protein Bhlhb5 and Notch signaling. *Development*. 2011; 138: 3199–3211. <https://doi.org/10.1242/dev.057281> PMID: 21750031
17. Mizuguchi R, Sugimori M, Takebayashi H, Kosako H, Nagao M, Yoshida S, et al. Combinatorial roles of Olig2 and Neurogenin2 in the coordinated induction of pan-neuronal and subtype-specific properties of motoneurons. *Neuron*. 2001; 31: 757–771. [https://doi.org/10.1016/S0896-6273\(01\)00413-5](https://doi.org/10.1016/S0896-6273(01)00413-5) PMID: 11567615
18. Takebayashi H, Nabeshima Y, Yoshida S, Chisaka O, Ikenaka K, Nabeshima YI. The basic helix-loop-helix factor Olig2 is essential for the development of motoneuron and oligodendrocyte lineages. *Curr Biol*. 2002; 12: 1157–1163. [https://doi.org/10.1016/S0960-9822\(02\)00926-0](https://doi.org/10.1016/S0960-9822(02)00926-0) PMID: 12121626
19. Scardigli R, Schuurmans C, Gradwohl G, Guillemot F. Crossregulation between Neurogenin2 and Pathways Specifying Neuronal Identity in the Spinal Cord. *Neuron*. 2001; 31: 203–217. [https://doi.org/10.1016/S0896-6273\(01\)00358-0](https://doi.org/10.1016/S0896-6273(01)00358-0) PMID: 11502253
20. Bertrand N, Castro DS, Guillemot F. Proneural genes and the specification of neural cell types. *Nat Rev Neurosci*. 2002; 3: 517–530. <https://doi.org/10.1038/nrn874> PMID: 12094208
21. Lu QR, Yuk D, Alberta J a, Zhu Z, Pawlitzky I, Chan J, et al. Sonic Hedgehog–Regulated Oligodendrocyte Lineage Genes Encoding bHLH Proteins in the Mammalian Central Nervous System. *Neuron*. 2000; 25: 317–329. [https://doi.org/10.1016/S0896-6273\(00\)80897-1](https://doi.org/10.1016/S0896-6273(00)80897-1) PMID: 10719888
22. Sugimori M, Nagao M, Bertrand N, Parras CM, Guillemot F, Nakafuku M. Combinatorial actions of patterning and HLH transcription factors in the spatiotemporal control of neurogenesis and gliogenesis in the developing spinal cord. *Development*. 2007; 134: 1617–29. <https://doi.org/10.1242/dev.001255> PMID: 17344230
23. Lacomme M, Liaubet L, Pituello F, Bel-Vialar S. NEUROG2 Drives Cell Cycle Exit of Neuronal Precursors by Specifically Repressing a Subset of Cyclins Acting at the G1 and S Phases of the Cell Cycle. *Mol Cell Biol*. 2012; 32: 2596–2607. <https://doi.org/10.1128/MCB.06745-11> PMID: 22547683
24. Ohtsuka T, Ishibashi M, Gradwohl G, Nakanishi S, Guillemot F, Kageyama R. Hes1 and Hes5 as notch effectors in mammalian neuronal differentiation. *EMBO J*. 1999; 18: 2196–2207. <https://doi.org/10.1093/emboj/18.8.2196> PMID: 10205173
25. Shimojo H, Ohtsuka T, Kageyama R. Dynamic expression of notch signaling genes in neural stem/progenitor cells. *Front Neurosci*. 2011; 5: 78. <https://doi.org/10.3389/fnins.2011.00078> PMID: 21716644
26. Kageyama R, Ohtsuka T, Kobayashi T. The Hes gene family: repressors and oscillators that orchestrate embryogenesis. *Development*. 2007; 134: 1243–1251. <https://doi.org/10.1242/dev.000786> PMID: 17329370
27. Meijer DH, Kane MF, Mehta S, Liu H, Harrington E, Taylor CM, et al. Separated at birth? The functional and molecular divergence of OLIG1 and OLIG2. *Nat Rev Neurosci*. Nature Publishing Group; 2012; 13: 819–831. <https://doi.org/10.1038/nrn3386> PMID: 23165259
28. Lee SK, Lee B, Ruiz EC, Pfaff SL. Olig2 and Ngn2 function in opposition to modulate gene expression in motor neuron progenitor cells. *Genes Dev*. 2005; 19: 282–294. <https://doi.org/10.1101/gad.1257105> PMID: 15655114
29. Ligon KL, Huillard E, Mehta S, Kesari S, Liu H, Alberta JA, et al. Olig2-Regulated Lineage-Restricted Pathway Controls Replication Competence in Neural Stem Cells and Malignant Glioma. *Neuron*. 2007; 53: 503–517. <https://doi.org/10.1016/j.neuron.2007.01.009> PMID: 17296553
30. Mehta S, Huillard E, Kesari S, Maire CL, Golebiowski D, Harrington EP, et al. The Central Nervous System-Restricted Transcription Factor Olig2 Opposes p53 Responses to Genotoxic Damage in Neural Progenitors and Malignant Glioma. *Cancer Cell*. Elsevier Inc.; 2011; 19: 359–371. <https://doi.org/10.1016/j.ccr.2011.01.035> PMID: 21397859
31. Son EY, Ichida JK, Wainger BJ, Toma JS, Rafuse VF, Woolf CJ, et al. Conversion of mouse and human fibroblasts into functional spinal motor neurons. *Cell Stem Cell*. 2011; 9: 205–218. <https://doi.org/10.1016/j.stem.2011.07.014> PMID: 21852222
32. Scialdone A, Tanaka Y, Jawaid W, Moignard V, Wilson NK, Macaulay IC, et al. Resolving early mesoderm diversification through single-cell expression profiling. *Nature*. Nature Publishing Group; 2016; 1–22. <https://doi.org/10.1038/nature18633> PMID: 27383781
33. Treutlein B, Lee QY, Camp JG, Mall M, Koh W, Ali S, et al. Dissecting direct reprogramming from fibroblast to neuron using single-cell RNA-seq. *Nature*. Nature Publishing Group; 2016; 534: 391–395. <https://doi.org/10.1038/nature18323> PMID: 27281220

34. Setty M, Tadmor MD, Reich-zeliger S, Angel O, Salame TM, Kathail P, et al. Articles Wishbone identifies bifurcating developmental trajectories from single-cell data. *Nat Biotechnol*. Nature Publishing Group; 2016; 34: 614–637. <https://doi.org/10.1038/nbt.3569> PMID: 27136076
35. Trapnell C, Cacchiarelli D, Grimsby J, Pokharel P, Li S, Morse M, et al. The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. *Nat Biotechnol*. Nature Publishing Group; 2014; 32: 381–386. <https://doi.org/10.1038/nbt.2859> PMID: 24658644
36. Shin J, Berg DA, Christian KM, Shin JY, Berg DA, Zhu Y, et al. Single-Cell RNA-Seq with Waterfall Reveals Molecular Cascades underlying Adult Neurogenesis Resource Single-Cell RNA-Seq with Waterfall Reveals Molecular Cascades underlying Adult Neurogenesis. *Stem Cell*. Elsevier Inc.; 2015; 17: 360–372. <https://doi.org/10.1016/j.stem.2015.07.013> PMID: 26299571
37. Gouti M, Tsakiridis A, Wymeersch FJ, Huang Y, Kleinjung J, Wilson V, et al. In vitro generation of neuro-mesodermal progenitors reveals distinct roles for wnt signalling in the specification of spinal cord and paraxial mesoderm identity. *PLoS Biol*. 2014; 12: e1001937. <https://doi.org/10.1371/journal.pbio.1001937> PMID: 25157815
38. Dasen JS, Liu J-P, Jessell TM. Motor neuron columnar fate imposed by sequential phases of Hox-c activity. *Nature*. 2003; 425: 926–933. <https://doi.org/10.1038/nature02051> PMID: 14586461
39. Philippidou P, Dasen JS. Hox Genes: Choreographers in Neural Development, Architects of Circuit Organization. *Neuron*. Elsevier Inc.; 2013; 80: 12–34. <https://doi.org/10.1016/j.neuron.2013.09.020> PMID: 24094100
40. Stifani N. Motor neurons and the generation of spinal motor neuron diversity. *Front Cell Neurosci*. 2014; 8: 293. <https://doi.org/10.3389/fncel.2014.00293> PMID: 25346659
41. Chamberlain CE, Jeong J, Guo C, Allen BL, McMahon AP. Notochord-derived Shh concentrates in close association with the apically positioned basal body in neural target cells and forms a dynamic gradient during neural patterning. *Development*. 2008; 135: 1097–1106. <https://doi.org/10.1242/dev.013086> PMID: 18272593
42. Dessaud E, Ribes V, Balaskas N, Yang LL, Pierani A, Kicheva A, et al. Dynamic assignment and maintenance of positional identity in the ventral neural tube by the morphogen sonic hedgehog. *PLoS Biol*. 2010; 8: e1000382. <https://doi.org/10.1371/journal.pbio.1000382> PMID: 20532235
43. Jeong J, McMahon AP. Growth and pattern of the mammalian neural tube are governed by partially overlapping feedback activities of the hedgehog antagonists patched 1 and Hhip1. *Development*. 2005; 132: 143–154. <https://doi.org/10.1242/dev.01566> PMID: 15576403
44. Velasco S, Ibrahim MM, Kakumanu A, Garipier G, Aydin B, Al-Sayegh MA, et al. A Multi-step Transcriptional and Chromatin State Cascade Underlies Motor Neuron Programming from Embryonic Stem Cells. *Cell Stem Cell*. 2016; <https://doi.org/10.1016/j.stem.2016.11.006> PMID: 27939218
45. Rhee HS, Closser M, Guo Y, Bashkirova E V., Tan GC, Gifford DK, et al. Expression of Terminal Effector Genes in Mammalian Neurons Is Maintained by a Dynamic Relay of Transient Enhancers. *Neuron*. Elsevier Inc.; 2016; 1–14. <https://doi.org/10.1016/j.neuron.2016.11.037> PMID: 27939581
46. Thaler JP, Koo SJ, Kania A, Lettieri K, Andrews S, Cox C, et al. A Postmitotic Role for Isl-Class LIM Homeodomain Proteins in the Assignment of Visceral Spinal Motor Neuron Identity. *Neuron*. 2004; 41: 337–350. [https://doi.org/10.1016/S0896-6273\(04\)00011-X](https://doi.org/10.1016/S0896-6273(04)00011-X) PMID: 14766174
47. Tanabe Y, William C, Jessell TM. Specification of motor neuron identity by the MNR2 homeodomain protein. *Cell*. 1998; 95: 67–80. [https://doi.org/10.1016/S0092-8674\(00\)81783-3](https://doi.org/10.1016/S0092-8674(00)81783-3) PMID: 9778248
48. Moris N, Pina C, Arias AM. Transition states and cell fate decisions in epigenetic landscapes. *Nat Rev Genet*. Nature Publishing Group; 2016; 17: 693–703. <https://doi.org/10.1038/nrg.2016.98> PMID: 27616569
49. Arber S, Han B, Mendelsohn M, Smith M, Jessell TM, Sockanathan S. Requirement for the homeobox gene Hb9 in the consolidation of motor neuron identity. *Neuron*. 1999; 23: 659–674. [https://doi.org/10.1016/S0896-6273\(01\)80026-X](https://doi.org/10.1016/S0896-6273(01)80026-X) PMID: 10482234
50. Tan GC, Mazzoni EO, Wichterle H. Iterative Role of Notch Signaling in Spinal Motor Neuron Diversification. *Cell Rep*. The Author(s); 2016; 16: 907–916. <https://doi.org/10.1016/j.celrep.2016.06.067> PMID: 27425621
51. Xiang C, Baubet V, Pal S, Holderbaum L, Tatard V, Jiang P, et al. RP58 / ZNF238 directly modulates proneurogenic gene levels and is required for neuronal differentiation and brain expansion. *Cell Death Differ*. Nature Publishing Group; 2011; 19: 692–702. <https://doi.org/10.1038/cdd.2011.144> PMID: 22095278
52. Oosterveen T, Kurdija S, Ensterö M, Uhde CW, Bergslund M, Sandberg M, et al. SoxB1-driven transcriptional network underlies neural-specific interpretation of morphogen signals. *Proc Natl Acad Sci U S A*. 2013; 110: 7330–5. <https://doi.org/10.1073/pnas.1220010110> PMID: 23589857
53. Chen JA, Huang YP, Mazzoni EO, Tan GC, Zavadi J, Wichterle H. Mir-17-3p controls spinal neural progenitor patterning by regulating Olig2/Irx3 cross-repressive loop. *Neuron*. 2011; 69: 721–735. <https://doi.org/10.1016/j.neuron.2011.01.014> PMID: 21338882

54. Shcherbo D, Murphy CS, Ermakova G V, Solovieva E a, Chepurnykh T V, Shcheglov AS, et al. Far-red fluorescent tags for protein imaging in living tissues. *Biochem J*. 2009; 418: 567–574. <https://doi.org/10.1042/BJ20081949> PMID: 19143658
55. Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, Vanin EF, et al. Correction of multi-gene deficiency in vivo using a single “self-cleaving” 2A peptide-based retroviral vector. *Nat Biotechnol*. 2004; 22: 589–594. <https://doi.org/10.1038/nbt957> PMID: 15064769
56. Dessaud E, Yang LL, Hill K, Cox B, Ulloa F, Ribeiro A, et al. Interpretation of the sonic hedgehog morphogen gradient by a temporal adaptation mechanism. *Nature*. 2007; 450: 717–720. <https://doi.org/10.1038/nature06347> PMID: 18046410
57. Artavanis-Tsakonas S. Notch Signaling: Cell Fate Control and Signal Integration in Development. *Science* (80-). 1999; 284: 770–776. <https://doi.org/10.1126/science.284.5415.770>
58. Selkoe D, Kopan R. Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. *Annu Rev Neurosci*. 2003; 26: 565–97. <https://doi.org/10.1146/annurev.neuro.26.041002.131334> PMID: 12730322
59. Louvi A, Artavanis-Tsakonas S. Notch signalling in vertebrate neural development. *Nat Rev Neurosci*. 2006; 7: 93–102. <https://doi.org/10.1038/nrn1847> PMID: 16429119
60. Hatakeyama J, Bessho Y, Katoh K, Ookawara S, Fujioka M, Guillemot F, et al. Hes genes regulate size, shape and histogenesis of the nervous system by control of the timing of neural stem cell differentiation. *Development*. 2004; 131: 5539–5550. <https://doi.org/10.1242/dev.01436> PMID: 15496443
61. Kong JH, Yang L, Briscoe J, Novitsch BG, Kong JH, Yang L, et al. Notch Activity Modulates the Responsiveness of Neural Progenitors to Sonic Hedgehog Signaling. *Dev Cell*. The Authors; 2015; 33: 373–387. <https://doi.org/10.1016/j.devcel.2015.03.005> PMID: 25936505
62. Fior R, Henrique D. A novel hes5/hes6 circuitry of negative regulation controls Notch activity during neurogenesis. *Dev Biol*. 2005; 281: 318–333. <https://doi.org/10.1016/j.ydbio.2005.03.017> PMID: 15893982
63. Kutejova E, Sasai N, Shah A, Gouti M, Briscoe J. Neural Progenitors Adopt Specific Identities by Directly Repressing All Alternative Progenitor Transcriptional Programs. *Dev Cell*. The Authors; 2016; 36: 639–653. <https://doi.org/10.1016/j.devcel.2016.02.013> PMID: 26972603
64. Seibt J, Schuurmans C, Gradwohl G, Dehay C, Vanderhaeghen P, Guillemot F. Neurogenin2 Specifies the Connectivity of Thalamic Neurons by Controlling Axon Responsiveness to Intermediate Target Cues. *Neuron*. 2003; 39: 439–452. [https://doi.org/10.1016/S0896-6273\(03\)00435-5](https://doi.org/10.1016/S0896-6273(03)00435-5) PMID: 12895419
65. Imayoshi I, Isomura A, Harima Y, Kawaguchi K, Kori H, Miyachi H, et al. Oscillatory control of factors determining multipotency and fate in mouse neural progenitors. *Science* (80-). 2013; 342: 1203–1208. <https://doi.org/10.1126/science.1242366> PMID: 24179156
66. Li Y, Hibbs MA, Gard AL, Shylo NA, Yun K. Genome-Wide Analysis of N1ICD/RBPJ Targets In Vivo Reveals Direct Transcriptional Regulation of Wnt, SHH, and Hippo Pathway Effectors by Notch1. *Stem Cells*. 2012; 30: 741–752. <https://doi.org/10.1002/stem.1030> PMID: 22232070
67. Cohen M, Page KM, Perez-Carrasco R, Barnes CP, Briscoe J. A theoretical framework for the regulation of Shh morphogen-controlled gene expression. *Development*. 2014; 141: 3868–3878. <https://doi.org/10.1242/dev.112573> PMID: 25294939
68. Lee SK, Jurata LW, Funahashi J, Ruiz EC, Pfaff SL. Analysis of embryonic motoneuron gene regulation: derepression of general activators function in concert with enhancer factors. *Development*. 2004; 131: 3295–3306. <https://doi.org/10.1242/dev.01179> PMID: 15201216
69. Samanta J, Kessler JJA. Interactions between ID and OLIG proteins mediate the inhibitory effects of BMP4 on oligodendroglial differentiation. *Development*. 2004; 131: 4131–4142. <https://doi.org/10.1242/dev.01273> PMID: 15280210
70. Sun Y, Meijer DH, Alberta JA, Mehta S, Kane MF, Tien AC, et al. Phosphorylation state of Olig2 regulates proliferation of neural progenitors. *Neuron*. 2011; 69: 906–917. <https://doi.org/10.1016/j.neuron.2011.02.005> PMID: 21382551
71. Meijer DH, Sun Y, Liu T, Kane MF, Alberta JA, Adelmant G, et al. An Amino Terminal Phosphorylation Motif Regulates Intracellular Compartmentalization of Olig2 in Neural Progenitor Cells. *J Neurosci*. 2014; 34: 8507–8518. <https://doi.org/10.1523/JNEUROSCI.0309-14.2014> PMID: 24948806
72. Li H, de Faria JP, Andrew P, Nitarska J, Richardson WD. Phosphorylation regulates OLIG2 cofactor choice and the motor neuron-oligodendrocyte fate switch. *Neuron*. 2011; 69: 918–929. <https://doi.org/10.1016/j.neuron.2011.01.030> PMID: 21382552
73. Setoguchi T, Kondo T. Nuclear export of OLIG2 in neural stem cells is essential for ciliary neurotrophic factor-induced astrocyte differentiation. *J Cell Biol*. 2004; 166: 963–8. <https://doi.org/10.1083/jcb.200404104> PMID: 15452140
74. Zhou J, Tien A-C, Alberta JA, Ficarro SB, Griveau A, Sun Y, et al. A Sequentially Priming Phosphorylation Cascade Activates the Gliomagenic Transcription Factor Olig2. *Cell Rep*. Elsevier Company.; 2017; 18: 3167–3177. <https://doi.org/10.1016/j.celrep.2017.03.003> PMID: 28355568

75. Ma YC, Song MR, Park JP, Henry Ho HY, Hu L, Kurtev M V., et al. Regulation of Motor Neuron Specification by Phosphorylation of Neurogenin 2. *Neuron*. 2008; 58: 65–77. <https://doi.org/10.1016/j.neuron.2008.01.037> PMID: 18400164
76. Hindley C, Ali F, McDowell G, Cheng K, Jones A, Guillemot F, et al. Post-translational modification of Ngn2 differentially affects transcription of distinct targets to regulate the balance between progenitor maintenance and differentiation. *Development*. 2012; 139: 1718–1723. <https://doi.org/10.1242/dev.077552> PMID: 22491944
77. Ali F, Hindley C, McDowell G, Deibler R, Jones A, Kirschner M, et al. Cell cycle-regulated multi-site phosphorylation of Neurogenin 2 coordinates cell cycling with differentiation during neurogenesis. *Development*. 2011; 138: 4267–4277. <https://doi.org/10.1242/dev.067900> PMID: 21852393
78. McDowell GS, Hindley CJ, Lippens G, Landrieu I, Philpott A. Phosphorylation in intrinsically disordered regions regulates the activity of Neurogenin2. *BMC Biochem*. 2014; 15: 24. <https://doi.org/10.1186/s12858-014-0024-3> PMID: 25374254
79. Shimojo H, Ohtsuka T, Kageyama R. Oscillations in Notch Signaling Regulate Maintenance of Neural Progenitors. *Neuron*. 2008; 58: 52–64. <https://doi.org/10.1016/j.neuron.2008.02.014> PMID: 18400163
80. Takebayashi K, Sasai Y, Sakai Y, Watanabe T, Nakanishi S, Kageyama R. Structure, chromosomal locus, and promoter analysis of the gene encoding the mouse helix-loop-helix factor HES-1. Negative autoregulation through the multiple N box elements. *J Biol Chem*. 1994; 269: 5150–5156. PMID: 7906273
81. Imayoshi I, Kageyama R. bHLH factors in self-renewal, multipotency, and fate choice of neural progenitor cells. *Neuron*. 2014; 82: 9–23. <https://doi.org/10.1016/j.neuron.2014.03.018> PMID: 24698265
82. Shimojo H, Isomura A, Ohtsuka T, Kori H, Miyachi H, Kageyama R. Oscillatory control of Delta-like1 in cell interactions regulates dynamic gene expression and tissue morphogenesis. *Genes Dev*. 2016; 30: 102–116. <https://doi.org/10.1101/gad.270785.115> PMID: 26728556
83. Sagner A, Briscoe J. Morphogen interpretation: concentration, time, competence, and signaling dynamics. *Wiley Interdiscip Rev Dev Biol*. 2017; e271. <https://doi.org/10.1002/wdev.271> PMID: 28319331
84. Stasiulewicz M, Gray SD, Mastromina I, Silva JC, Bjorklund M, Seymour PA, et al. A conserved role for Notch signaling in priming the cellular response to Shh through ciliary localisation of the key Shh transducer Smo. *Development*. 2015; 142: 2291–2303. <https://doi.org/10.1242/dev.125237> PMID: 25995356
85. Gaber ZB, Butler SJ, Novitch BG. PLZF regulates fibroblast growth factor responsiveness and maintenance of neural progenitors. Polleux F, editor. *PLoS Biol*. 2013; 11: e1001676. <https://doi.org/10.1371/journal.pbio.1001676> PMID: 24115909
86. Sasai N, Kutejova E, Briscoe J. Integration of signals along orthogonal axes of the vertebrate neural tube controls progenitor competence and increases cell diversity. *PLoS Biol*. 2014; 12: e1001907. <https://doi.org/10.1371/journal.pbio.1001907> PMID: 25026549
87. Ito T, Udaka N, Yazawa T, Okudela K, Hayashi H, Sudo T, et al. Basic helix-loop-helix transcription factors regulate the neuroendocrine differentiation of fetal mouse pulmonary epithelium. *Development*. 2000; 127: 3913–21. PMID: 10952889
88. Bylund M, Andersson E, Novitch BG, Muhr J. Vertebrate neurogenesis is counteracted by Sox1-3 activity. *Nat Neurosci*. 2003; 6: 1162–1168. <https://doi.org/10.1038/nn1131> PMID: 14517545
89. Lo L, Dormand E, Greenwood A, Anderson DJ. Comparison of the generic neuronal differentiation and neuron subtype specification functions of mammalian achaete-scute and atonal homologs in cultured neural progenitor cells. *Development*. 2002; 129: 1553–1567. PMID: 11923194
90. Novitch BG, Wichterle H, Jessell TM, Sockanathan S. A requirement for retinoic acid-mediated transcriptional activation in ventral neural patterning and motor neuron specification. *Neuron*. 2003; 40: 81–95. PMID: 14527435
91. Ran FA, Hsu PD, Lin CY, Gootenberg JS, Konermann S, Trevino AE, et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. *Cell*. 2013; 154: 1380–1389. <https://doi.org/10.1016/j.cell.2013.08.021> PMID: 23992846
92. Lumpkin EA, Collisson T, Parab P, Omer-Abdalla A, Haeberle H, Chen P, et al. Math1-driven GFP expression in the developing nervous system of transgenic mice. *Gene Expr Patterns*. 2003; 3: 389–395. [https://doi.org/10.1016/S1567-133X\(03\)00089-9](https://doi.org/10.1016/S1567-133X(03)00089-9) PMID: 12915300